•a‘Ô‚©‚玡—ÂÖ-ŽŸ‚Ì50”N‚Ìi•à‚ð‚ß‚´‚µ‚Ä-

ƒvƒƒOƒ‰ƒ€

“ú’ö•\ 5ŒŽ17“úi‰Îj ‘O“ú(PDF) “ú’ö•\ 5ŒŽ18“úi…j 1“ú–Ú(PDF)

“ú’ö•\ 5ŒŽ19“úi–Øj 2“ú–Ú(PDF) “ú’ö•\ 5ŒŽ20“úi‹àj 3“ú–Ú(PDF)

“Œ“ú–{‘åkЋً}ƒtƒH[ƒ‰ƒ€

5ŒŽ20“úi‹àj 15:15`17:00@1A‰ïêi1†ŠÙ2ŠKƒZƒ“ƒ`ƒ…ƒŠ[ƒz[ƒ‹j

À’·F
‘c•ƒ]@Œ³i‘æ52‰ñ“ú–{_ŒoŠw‰ïŠwp‘å‰ï@‘å‰ï’·j
 
…àV@‰p—mi“ú–{_ŒoŠw‰ï@‘ã•\—Ž–j

Šî’²u‰‰

ЊQ‚ÌŒ»ê‚©‚ç

 
‚‹´@’qiŠâŽèˆã‰È‘åŠw_Œo“à‰Èj
 
•l“o@•¶Žõi‚Í‚Ü‚Æ_Œo“à‰ÈƒNƒŠƒjƒbƒNj

ЊQ‚ÌŒ»ê‚©‚ç

 
–Ø@³Žui“Œ–k‘åŠw_Œo“à‰Èj

ЊQ‚ÌŒ»ê‚©‚çiƒCƒ“ƒ^[ƒlƒbƒg’†Œpj

 
ŠâŒ©@‰­äiŠâŒ©_Œo“à‰Èˆã‰@j

ЊQ‚ÌŒ»ê‚©‚ç

 
‰Fì@‹`ˆêi•Ÿ“‡Œ§—§ˆã‰È‘åŠw_Œo“à‰Èj

ЊQŽx‰‡|s­

 
’†“c@ŸŒÈii‘OjŒú¶˜J“­ÈŽ¾•a‘Îô‰Ûj

Žw’è”­Œ¾

ЊQŽx‰‡

 
ŽR‘º@Ci•Ÿˆä‘åŠwˆãŠw•”•‘®•a‰@_Œo“à‰Èj

ЊQŽx‰‡

 
‰¬–ì@”üŒbŽqi–k—¢‘åŠw_Œo“à‰Èj

‘‡“¢˜_

ƒtƒƒA‚ðŒð‚¦‚½ƒpƒlƒ‹ƒfƒBƒXƒJƒbƒVƒ‡ƒ“

ƒy[ƒWƒgƒbƒv‚Ö↑

‘å‰ï’·u‰‰

_Œo•Ï«Ž¾Š³‚Ì•ªŽq•W“IŽ¡—Âð–ÚŽw‚µ‚Ä

5ŒŽ18“úi…j 13:30`14:30@1A‰ïêi1†ŠÙ2ŠKƒZƒ“ƒ`ƒ…ƒŠ[ƒz[ƒ‹j

À’·F
ûü‹´@ºi–¼ŒÃ‰®‘åŠw–¼—_‹³Žö^“ŒŠC’†‰›•a‰@–¼—_‰@’·j
‰‰ŽÒF
‘c•ƒ]@Œ³i–¼ŒÃ‰®‘åŠw_Œo“à‰Èj

ƒy[ƒWƒgƒbƒv‚Ö↑

“Á•Êu‰‰

“Á•Êu‰‰1
Past, present, and future of polyglutamine expansion disease

5ŒŽ17“úi‰Îj 16:45`18:30@3A‰ïêi3†ŠÙ3ŠK‘Û‰ï‹cŽºj

À’·F
Š‹Œ´@–ÎŽ÷i—鎭ˆã—ÉȊw‘åŠw•ÛŒ’‰q¶Šw•”ˆã—ÕŸŽƒŠw‰Èj
‰‰ŽÒF
Kenneth H. FischbeckiNeurogenetics Branch, NINDS, NIH, USAj
“Á•Êu‰‰2
1•ªŽq‚©‚ç”]‚ÖF•¡ŽGƒVƒXƒeƒ€‚ð—‰ð‚·‚éVŠT”O

5ŒŽ17“úi‰Îj 16:45`18:30@3A‰ïêi3†ŠÙ3ŠK‘Û‰ï‹cŽºj

À’·F
–öàV@M•vi“Œ‹žH‰È‘åŠwˆã—Õی’Šw•”j
‰‰ŽÒF
–ö“c@•q—Yi‘åã‘åŠw‘åŠw‰@¶–½‹@”\Œ¤‹†‰ÈCNICT ”]î•ñ’ÊMC—Œ¤QBiCj

ƒy[ƒWƒgƒbƒv‚Ö↑

ƒI[ƒvƒjƒ“ƒOƒZƒ~ƒi[

”]‚̉‘Y«‚ÌÅ‘OüF_Œo‹@”\‰ñ•œEƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“‚Ì‹ß–¢—ˆ‚Ö‚Ì“W–]

5ŒŽ17“úi‰Îj 16:45`18:30@2F‰ïêi2†ŠÙ3ŠK‰ï‹cŽº234j

À’·F
‰Fì@‹`ˆêi•Ÿ“‡Œ§—§ˆã‰È‘åŠwˆãŠw•”_Œo“à‰ÈŠwj
 
”ö“¡@°•Fi“Œ‹ž‘åŠw‘åŠw‰@ˆãŠwŒnŒ¤‹†‰È_Œo¶‰»Šw•ª–ìj

1D”]‚Ì’·Šú‰Â‘Y«‚Ì•ªŽq‹@\

‰‰ŽÒF
”ö“¡@°•Fi“Œ‹ž‘åŠw‘åŠw‰@ˆãŠwŒnŒ¤‹†‰È_Œo¶‰»Šw•ª–ìj

2DŽ¥‹CŽhŒƒ‚É‚æ‚éƒqƒg’†•_Œo‚ł̉‘Y«‚Ì—U“±FQPS

‰‰ŽÒF
‰Fì@‹`ˆêi•Ÿ“‡Œ§—§ˆã‰È‘åŠwˆãŠw•”_Œo“à‰ÈŠwj

3D”]‘¹Œã‚Ì‹@”\‰ñ•œ‚Æ”]‚̉‘Y«i—Õ°j

‰‰ŽÒF
•ž•”@Œ›–¾iX”V‹{•a‰@_ŒoƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“Œ¤‹†•”j

ƒy[ƒWƒgƒbƒv‚Ö↑

“ú–{_ŒoŠw‰ï2010”N“x“è—ÑÜŽóÜŽÒµ‘Òu‰‰

5ŒŽ18“úi…j 13:10`13:30@1A‰ïêi1†ŠÙ2ŠKƒZƒ“ƒ`ƒ…ƒŠ[ƒz[ƒ‹j

À’·F
‘c•ƒ]@Œ³i–¼ŒÃ‰®‘åŠw_Œo“à‰Èj
 
…àV@‰p—mi“ú–{_ŒoŠw‰ï‘ã•\—Ž–C“Œ‹žˆã‰ÈŽ•‰È‘åŠw‘åŠw‰@”]_Œo•a‘ÔŠw•ª–ìj

ƒp[ƒLƒ“ƒ\ƒ“•a‚É‚¨‚¯‚é”F’m‹@”\áŠQ‚ÌŒ¤‹†F‚Æ‚­‚ɎЉï“I”F’m‹@”\áŠQ‚ÆG“‘Ì‹@”\áŠQ‚Æ‚ÌŠÖ˜A‚ɂ‚¢‚Ä

‰‰ŽÒF
‰Í‘º@–žiº˜a‘åŠwˆãŠw•”“à‰ÈŠwuÀ_Œo“à‰ÈŠw•”–åj

ƒy[ƒWƒgƒbƒv‚Ö↑

‹³ˆçu‰‰

‹³ˆçu‰‰1
–¾“ú‚©‚ç–𗧂ˆã—ÈÀ‘SF_Œo“à‰Èf—Âɖ𗧂ƒƒfƒBƒG[ƒVƒ‡ƒ“ƒ‚ƒfƒ‹

5ŒŽ18“úi…j 7:45`8:20@2D‰ïêi2†ŠÙ2ŠK‰ï‹cŽº224j

À’·F
ç—t@iiŽD–yŽR‚Ìã•a‰@j
‰‰ŽÒF
ˆÀ“¡@“N˜Niˆ¤’mŒ§Œú¶˜AˆÀéX¶•a‰@_Œo“à‰Èj
‹³ˆçu‰‰2
‚æ‚­‚í‚©‚éˆãŠwŒ¤‹†—Ï—Žwj

5ŒŽ18“úi…j 7:45`8:20@2E‰ïêi2†ŠÙ3ŠK‰ï‹cŽº232{233j

À’·F
‹gˆä@•¶‹Ïi“ŒŠC‘åŠw_Œo“à‰Èj
‰‰ŽÒF
”Ñ“‡@û€•Fi–¼ŒÃ‰®‘åŠw‘åŠw‰@ˆãŠwŒnŒ¤‹†‰È¶–½—Ï—ˆÏˆõ‰ïj
‹³ˆçu‰‰3
–TŽîᇫ_ŒoÇŒóŒQupdate

5ŒŽ18“úi…j 7:45`8:20@2F‰ïêi2†ŠÙ3ŠK‰ï‹cŽº234j

À’·F
“c’†@ŒbŽqi‹à‘òˆã‰È‘åŠw_Œo“à‰ÈŠwj
‰‰ŽÒF
Œ¢’Ë@‹MiŠò•Œ‘åŠw‘åŠw‰@ˆãŠwŒnŒ¤‹†‰È_Œo“à‰ÈE˜V”NŠw•ª–ìj
‹³ˆçu‰‰4
‘½Œn“ˆÞkÇ‚Ì•Ï«‚Ì‚Í‚¶‚Ü‚è‚Í_Œo×–E‚©‚ç‚©ƒOƒŠƒA×–E‚©‚ç‚©

5ŒŽ18“úi…j 7:45`8:20@4A‰ïêi4†ŠÙ1ŠK”’’¹ƒz[ƒ‹i–kjj

À’·F
‰Á“¡@M‰îi’¹Žæ‘åŠwˆãŠw•”•‘®”]Š²«Ž¾Š³Œ¤‹†Ž{Ý”]_Œo•a—•”–åj

‘½Œn“ˆÞkÇ\ƒVƒkƒNƒŒƒCƒ“‚Æ_Œo×–E•Ï«\

‰‰ŽÒF
‹g“c@áÁ—iˆ¤’mˆã‰È‘åŠw‰Á—îˆã‰ÈŠwŒ¤‹†Šj

‘½Œn“ˆÞkÇ‚Ì•Ï«‚Ì‚Í‚¶‚Ü‚è‚Í_Œo×–E‚©‚ç‚©ƒOƒŠƒA×–E‚©‚ç‚©FƒOƒŠƒA×–E

‰‰ŽÒF
ŽR“c@Œõ‘¥i‘—§•a‰@‹@\‚³‚¢‚ª‚½•a‰@—Õ°Œ¤‹†•”j
‹³ˆçu‰‰5
‘O“ª‘¤“ª—t•Ï«ÇiFTLDj‚Ì•ª—Þ‚Æ•a‘Ôupdate

5ŒŽ18“úi…j 7:45`8:20@4B‰ïêi4†ŠÙ1ŠK”’’¹ƒz[ƒ‹i“ìjj

À’·F
‰ª–{@KŽsiŒQ”n‘åŠw‘åŠw‰@ˆãŠwŒnŒ¤‹†‰È”]_Œo“à‰ÈŠwj
‰‰ŽÒF
’†–ì@¡Ž¡iŽ©Ž¡ˆã‰È‘åŠw“à‰ÈŠwuÀ_Œo“à‰ÈŠw•”–åj
‹³ˆçu‰‰6
–Ɖu—}§Š³ŽÒ‚É‚¨‚¯‚é_ŒoŽ¾Š³

5ŒŽ19“úi–Øj 7:45`8:20@2D‰ïêi2†ŠÙ2ŠK‰ï‹cŽº224j

À’·F
Œüˆä@‰hˆê˜Yi–¼ŒÃ‰®ˆã—ÃZƒ“ƒ^[_Œo“à‰Èj
‰‰ŽÒF
ŠÝ“c@C“ñi‚ª‚ñEŠ´õǃZƒ“ƒ^[“s—§‹îž•a‰@”]_Œo“à‰Èj
‹³ˆçu‰‰7
_ŒoŽ¾Š³‚Æ“œ½¶•¨ŠwFV‚½‚ȶ–½½‚Ì–ðŠ„

5ŒŽ19“úi–Øj 7:45`8:20@2E‰ïêi2†ŠÙ3ŠK‰ï‹cŽº232{233j

À’·F
‰Á“¡@ä•viŽRŒ`‘åŠwˆãŠw•”‘æ3“à‰Èj
‰‰ŽÒF
•“¡@‘½’ØYi“¡“c•ÛŒ’‰q¶‘åŠwˆãŠw•””]_Œo“à‰ÈŠwj
‹³ˆçu‰‰8
ŋ߂̈««”]Žîᇎ¡—ÂÌi•à

5ŒŽ19“úi–Øj 7:45`8:20@2F‰ïêi2†ŠÙ3ŠK‰ï‹cŽº234j

À’·F
…’J@’q•Fi“ú–{‘åŠw‘‡ŠwŒ¤‹†Šj
‰‰ŽÒF
Žá—Ñ@r•Fi–¼ŒÃ‰®‘åŠw‘åŠw‰@ˆãŠwŒnŒ¤‹†‰È”]_ŒoŠO‰ÈŠwj
‹³ˆçu‰‰9
”F’mÇ‚ÌBPSD‚Ì–ò•¨Ž¡—ÃF¸_‰È‚©‚ç‚̃ƒbƒZ[ƒW

5ŒŽ19“úi–Øj 7:45`8:20@3A‰ïêi3†ŠÙ3ŠK‘Û‰ï‹cŽºj

À’·F
—L‘º@Œö—Çi‘埕a‰@_Œo“à‰Èj
‰‰ŽÒF
‹´–{@‰qiŒF–{‘åŠwˆãŠw•”•‘®•a‰@_Œo¸_‰Èj
‹³ˆçu‰‰10
ƒp[ƒLƒ“ƒ\ƒ“•a‚Ì”F’m‹@”\áŠQ‚Ìf•û

5ŒŽ19“úi–Øj 7:45`8:20@4A‰ïêi4†ŠÙ1ŠK”’’¹ƒz[ƒ‹i–kjj

À’·F
¬Ž­@K¶i–¼ŒÃ‰®Žs—§‘åŠw‘åŠw‰@ˆãŠwŒ¤‹†‰È_Œo“à‰Èj
‰‰ŽÒF
‰Í‘º@–žiº˜a‘åŠwˆãŠw•”“à‰ÈŠwuÀ_Œo“à‰ÈŠw•”–åj
‹³ˆçu‰‰11
”][ÇÄ”­—\–hupdate

5ŒŽ19“úi–Øj 7:45`8:20@4B‰ïêi4†ŠÙ1ŠK”’’¹ƒz[ƒ‹i“ìjj

À’·F
r–Ø@M•vié‹Êˆã‰È‘åŠw_Œo“à‰Èj
‰‰ŽÒF
“c’†@k‘¾˜Yi•xŽR‘åŠw•‘®•a‰@_Œo“à‰Èj
‹³ˆçu‰‰12
”]MRI‚©‚ç•Ï«Ž¾Š³‚Ìf’f‚É”—‚é\•a—C—Õ°‚̑Δ䂩‚ç\

5ŒŽ20“úi‹àj 7:45`8:20@2D‰ïêi2†ŠÙ2ŠK‰ï‹cŽº224j

À’·F
´…@‹P•vi’é‹ž‘åŠwˆãŠw•”_Œo“à‰Èj
‰‰ŽÒF
“n•Ó@G‹vi–¼ŒÃ‰®‘åŠw_Œo“à‰Èj
‹³ˆçu‰‰13
_Œo“à‰Èˆã‚É•K—v‚Ȉâ“`ƒJƒEƒ“ƒZƒŠƒ“ƒO

5ŒŽ20“úi‹àj 7:45`8:20@2F‰ïêi2†ŠÙ3ŠK‰ï‹cŽº234j

À’·F
Œã“¡@‡i“Œ‹ž‘åŠw_Œo“à‰Èj
‰‰ŽÒF
‹g“c@–MLiMB‘åŠwˆãŠw•”_Œo“ï•aŠwuÀj
‹³ˆçu‰‰14
‚æ‚­‚í‚©‚éCOI iconflict of interestj

5ŒŽ20“úi‹àj 7:45`8:20@3A‰ïêi3†ŠÙ3ŠK‘Û‰ï‹cŽºj

À’·F
²ŒÃ“c@ŽO˜Yi“ªŽR•a‰@_Œo“à‰Èj
‰‰ŽÒF
‘]ª@ŽO˜Yi“ú–{ˆãŠw‰ï—˜‰v‘Š”½ˆÏˆõ‰ïi“¿“‡‘åŠw‘åŠw‰@ƒwƒ‹ƒXƒoƒCƒIƒTƒCƒGƒ“ƒXŒ¤‹†•”jj
‹³ˆçu‰‰15
Ž©ŒÈ–Ɖu«_Œo‹ØÚ‡•”Ž¾Š³‚Ì•a‘Ô‚ÆŽ¡—Ã

5ŒŽ20“úi‹àj 7:45`8:20@4A‰ïêi4†ŠÙ1ŠK”’’¹ƒz[ƒ‹i–kjj

À’·F
²‹´@Œ÷iˆ¤’mˆã‰È‘åŠw–¼—_‹³Žöj
‰‰ŽÒF
–{‘º@­Ÿi’·è‘åŠw‘åŠw‰@ˆãŽ•–òŠw‘‡Œ¤‹†‰È‘æˆê“à‰È_Œo“à‰Èj
‹³ˆçu‰‰16
“«•Ð“ª’É‚Ì‘Îô‚ÆŽ¡—Ã

5ŒŽ20“úi‹àj 7:45`8:20@4B‰ïêi4†ŠÙ1ŠK”’’¹ƒz[ƒ‹i“ìjj

À’·F
’†“‡@Œ’“ñi’¹Žæ‘åŠwˆãŠw•”ˆãŠw‰È”]_Œoˆã‰ÈŠwuÀ”]_Œo“à‰ÈŠw•ª–ìj
‰‰ŽÒF
´…@—˜•FiŒcœä‹`m‘åŠwˆãŠw•”_Œo“à‰Èj

ƒy[ƒWƒgƒbƒv‚Ö↑

ƒzƒbƒgƒgƒsƒbƒNƒX

ƒzƒbƒgƒgƒsƒbƒNƒX1@Neuromyelitis opticaiNMOj‚Ì‚·‚ׂÄ

5ŒŽ18“úi…j 8:30`9:20@1A‰ïêi1†ŠÙ2ŠKƒZƒ“ƒ`ƒ…ƒŠ[ƒz[ƒ‹j

À’·F
Ž…ŽR@‘×li‘—§¸_E_Œoˆã—ÃŒ¤‹†ƒZƒ“ƒ^[•a‰@j
‰‰ŽÒF
“¡Œ´@ˆê’ji“Œ–k‘åŠw‘åŠw‰@ˆãŠwŒnŒ¤‹†‰È‘½”­«d‰»ÇŽ¡—ÊwŠñ•uÀj
ƒzƒbƒgƒgƒsƒbƒNƒX2@‘½”­«d‰»Ç‚ÌÅV‚Ì•a‘Ô‚ÆŽ¡—Ã

5ŒŽ18“úi…j 9:30`10:20@1A‰ïêi1†ŠÙ2ŠKƒZƒ“ƒ`ƒ…ƒŠ[ƒz[ƒ‹j

À’·F
Ö“c@F•Fi‹ž“s–¯ˆã˜A’†‰›•a‰@_Œo“à‰Èj

Pathophysiology of progressive multiple sclerosis: studies in a genetically manipulated murine model

‰‰ŽÒF
David PleasureiInstitute for Pediatric Regenerative Research and Department of Neurology, UC Davis, USAj

‘½”­«d‰»Ç‚ÆÁ‰»ŠÇ–Ɖu

‰‰ŽÒF
ŽR‘º@—²i‘—§¸_E_Œoˆã—ÃŒ¤‹†ƒZƒ“ƒ^[_ŒoŒ¤‹†Š–ƉuŒ¤‹†•”j
ƒzƒbƒgƒgƒsƒbƒNƒX3@_Œo“à‰ÈŽ¡—ÃKƒCƒhƒ‰ƒCƒ“G‚Ä‚ñ‚©‚ñ

5ŒŽ18“úi…j 10:30`11:20@1A‰ïêi1†ŠÙ2ŠKƒZƒ“ƒ`ƒ…ƒŠ[ƒz[ƒ‹j

À’·F
•½“c@KˆêiàÕ‹¦ˆã‰È‘åŠw_Œo“à‰Èj
‰‰ŽÒF
’Ò@’åriŽY‹Æˆã‰È‘åŠw_Œo“à‰Èj
ƒzƒbƒgƒgƒsƒbƒNƒX4@ƒp[ƒLƒ“ƒ\ƒ“•aŽ¡—ÃKƒCƒhƒ‰ƒCƒ“2011

5ŒŽ19“úi–Øj 8:30`9:20@1A‰ïêi1†ŠÙ2ŠKƒZƒ“ƒ`ƒ…ƒŠ[ƒz[ƒ‹j

À’·F
‚‹´@—Ç•ãi‹ž“s‘åŠw‘åŠw‰@ˆãŠwŒ¤‹†‰È—Õ°_ŒoŠwj
‰‰ŽÒF
•“c@“Äi“Œ–k‘åŠw•a‰@_Œo“à‰Èj
ƒzƒbƒgƒgƒsƒbƒNƒX5@Ž©ŒÈR‘Ì‚©‚ç‚Ý‚½ƒjƒ…[ƒƒpƒ`[

5ŒŽ19“úi–Øj 9:30`10:20@1A‰ïêi1†ŠÙ2ŠKƒZƒ“ƒ`ƒ…ƒŠ[ƒz[ƒ‹j

À’·F
ŒIŽR@Ÿi”]_ŒoƒZƒ“ƒ^[‘å“c‹L”O•a‰@j
‰‰ŽÒF
“í@ii‹ß‹E‘åŠw_Œo“à‰Èj
ƒzƒbƒgƒgƒsƒbƒNƒX6@_Œo“à‰ÈŽ¡—ÃKƒCƒhƒ‰ƒCƒ“G‘½”­«d‰»Ç

5ŒŽ19“úi–Øj 10:30`11:20@1A‰ïêi1†ŠÙ2ŠKƒZƒ“ƒ`ƒ…ƒŠ[ƒz[ƒ‹j

À’·F
–쑺@‹±ˆêié‹Êˆã‰È‘åŠw‘‡ˆã—ÃZƒ“ƒ^[_Œo“à‰Èj
‰‰ŽÒF
‹g—Ç@ˆêi‹ãB‘åŠw‘åŠw‰@ˆãŠwŒ¤‹†‰@_Œo“à‰Èj
ƒzƒbƒgƒgƒsƒbƒNƒX7@RNA splicingˆÙí‚Æ_ŒoŽ¾Š³

5ŒŽ19“úi–Øj 13:15`14:05@1A‰ïêi1†ŠÙ2ŠKƒZƒ“ƒ`ƒ…ƒŠ[ƒz[ƒ‹j

À’·F
‰ºà_@riŽD–yˆã‰È‘åŠw_Œo“à‰Èj
‰‰ŽÒF
‘å–ì@‹ÔŽii–¼ŒÃ‰®‘åŠw‘åŠw‰@ˆãŠwŒnŒ¤‹†‰È_Œoˆâ“`î•ñŠwj
ƒzƒbƒgƒgƒsƒbƒNƒX8@ALS‚Ì•a—FÅV‚Ì’mŒ©

5ŒŽ20“úi‹àj 8:30`9:20@1A‰ïêi1†ŠÙ2ŠKƒZƒ“ƒ`ƒ…ƒŠ[ƒz[ƒ‹j

À’·F
Š‹Œ´@–ÎŽ÷i—鎭ˆã—ÉȊw‘åŠw•ÛŒ’‰q¶Šw•”ˆã—ÕŸŽƒŠw‰Èj
‰‰ŽÒF
‘ºŽR@”É—Yi“Œ‹ž“sŒ’N’·Žõˆã—ÃZƒ“ƒ^[‚—îŽÒƒuƒŒƒCƒ“ƒoƒ“ƒNj
ƒzƒbƒgƒgƒsƒbƒNƒX9@_Œo“à‰ÈŽ¡—ÃKƒCƒhƒ‰ƒCƒ“G”F’mÇ

5ŒŽ20“úi‹àj 9:30`10:20@1A‰ïêi1†ŠÙ2ŠKƒZƒ“ƒ`ƒ…ƒŠ[ƒz[ƒ‹j

À’·F
´…@‹P•vi’é‹ž‘åŠwˆãŠw•”_Œo“à‰Èj
‰‰ŽÒF
’†“‡@Œ’“ñi’¹Žæ‘åŠwˆãŠw•”ˆãŠw‰È”]_Œoˆã‰ÈŠwuÀ”]_Œo“à‰ÈŠw•ª–ìj

ƒy[ƒWƒgƒbƒv‚Ö↑

ƒjƒ…[ƒƒTƒCƒGƒ“ƒXƒZƒbƒVƒ‡ƒ“

ƒjƒ…[ƒƒTƒCƒGƒ“ƒXƒZƒbƒVƒ‡ƒ“1
Lee Silverman Voice Treatment; Rehabilitative Therapy for People with Parkinsonfs

5ŒŽ19“úi–Øj 10:45`11:30@3A‰ïêi3†ŠÙ3ŠK‘Û‰ï‹cŽºj

À’·F
‘º“c@”ü•äi‘—§¸_E_Œoˆã—ÃŒ¤‹†ƒZƒ“ƒ^[j
‰‰ŽÒF
Cynthia M FoxiNational Center for Voice and Speechj
ƒjƒ…[ƒƒTƒCƒGƒ“ƒXƒZƒbƒVƒ‡ƒ“2@ƒp[ƒLƒ“ƒ\ƒ“ÇŒó‚ð•û’öŽ®‚Å‰ð‚±‚¤

5ŒŽ19“úi–Øj 14:45`16:45@1B‰ïêi1†ŠÙ3ŠK‰ï‹cŽº131{132j

À’·F
¬–쎛@Gi¼‘½‰ê•a‰@_Œo“à‰Èj
‰‰ŽÒF
²ŒÃ“c@ŽO˜Yi‘—§•a‰@‹@\“ªŽR•a‰@j
ƒjƒ…[ƒƒTƒCƒGƒ“ƒXƒZƒbƒVƒ‡ƒ“3@_ŒoƒCƒ[ƒWƒ“ƒOŽè–@‚ð—p‚¢‚½Šç”F’m‹@\‚̉ð–¾

5ŒŽ19“úi–Øj 14:45`16:45@1C‰ïêi1†ŠÙ3ŠK‰ï‹cŽº133{134j

À’·F
”ò¼@ÈŽOi‹ãB‘åŠw‘åŠw‰@ˆãŠwŒ¤‹†‰@”]Œ¤—Õ°_Œo¶—j
‰‰ŽÒF
Š`–Ø@—²‰îi¶—ŠwŒ¤‹†Š“‡¶—Œ¤‹†Œnj

ƒy[ƒWƒgƒbƒv‚Ö↑

AAN-JSN Joint Symposiumi“ú•Ä_ŒoŠw‰ï‡“¯ƒVƒ“ƒ|ƒWƒEƒ€j

Keynote Session

5ŒŽ18“úi…j 14:30`15:00@1A‰ïêi1†ŠÙ2ŠKƒZƒ“ƒ`ƒ…ƒŠ[ƒz[ƒ‹j

À’·F
‹ààV@ˆê˜Yi“ú–{Šwp‰ï‹c‰ï’·C‘Ûˆã—ÕŸŽƒ‘åŠw‘åŠw‰@‘åŠw‰@’·j
JS-K-1
The Japanese Society of Neurology and the American Academy of Neurology:Response to Global Imperatives

Robert GriggsiPresident of American Academy of Neurology; Department of Neurology, University of Rochester School of Medicine and Dentistry, USAj

JS-K-2
American Academy of Neurology (AAN) and Japanese Society of Neurology (JSN) FBeyond the Pacific

…àV@‰p—mi“ú–{_ŒoŠw‰ï‘ã•\—Ž–C“Œ‹žˆã‰ÈŽ•‰È‘åŠw‘åŠw‰@”]_Œo•a‘ÔŠw•ª–ìj

1DALS

5ŒŽ18“úi…j 15:00`16:45@1A‰ïêi1†ŠÙ2ŠKƒZƒ“ƒ`ƒ…ƒŠ[ƒz[ƒ‹j

À’·F
‘c•ƒ]@Œ³i–¼ŒÃ‰®‘åŠw_Œo“à‰Èj
 
Don W. ClevelandiLudnig institute, University of California at San Diego, USAj
JS-1-1
Clinical or Patient-Oriented Research to Find the Pathogeneses and Cause of ALS

ŽO–{@”ŽiDepartment of Neurology, Columbia University, USAj

JS-1-2
The basis for selective neuronal vulnerability in ALS:mechanisms and therapy for ALS

Don W. ClevelandiLudwig Institute, University of California at San Diego, USAj

JS-1-3
Oligodendroglia are an unexpected major contributor to ALS and Neurodegeneration

Jeffrey D. RothsteiniJohns Hopkins University, USAj

JS-1-4
Optineurin in ALS

ìã@GŽjiL“‡‘åŠwŒ´”š•úŽËüˆã‰ÈŠwŒ¤‹†Šj

JS-1-5
Failure of RNA editing and the pathogenesis of ALS

Šs@Li“Œ‹ž‘åŠw_Œo“à‰Èj

2DƒAƒ‹ƒcƒnƒCƒ}[•a

5ŒŽ18“úi…j 15:00`16:45@4B‰ïêi4†ŠÙ1ŠK”’’¹ƒz[ƒ‹i“ìjj

À’·F
Šâ’Ø@ˆÐi“Œ‹ž‘åŠw‘åŠw‰@ˆãŠwŒnŒ¤‹†‰È_Œo•a—Šwj
 
Michael W. WeineriDepartment of Radiology, San Francisco VA Medical Center/UCSF, USAj
JS-2-1
Mechanisms and Treatment of Neuronal Dysfunction in Models of Alzheimerfs Disease

Lennart MuckeiGladstone Institute of Neurological Disease and UCSF, USAj

JS-2-2
Biomakers for Predicting and Monitoring Progression of Alzheimerfs Disease:The Alzheimerfs Disease Neuroimaging Initiative

Michael W. WeineriDepartment of Radiology, San Francisco VA Medical Center/UCSF, USAj

JS-2-3
Molecular pathology and disease-modifying therapies for Alzheimerfs disease

Šâ’Ø@ˆÐi“Œ‹ž‘åŠw‘åŠw‰@ˆãŠwŒnŒ¤‹†‰È_Œo•a—Šwj

JS-2-4
The future of Alzheimerfs disease:opportunities and challenges in drug development

“¡–{@—zŽqiƒtƒ@ƒCƒU[»–òŠ”Ž®‰ïŽÐŠJ”­•”j

ƒy[ƒWƒgƒbƒv‚Ö↑

the Movement Disorder Society
  • East Asian Neurology Forum ‚ÍThe Movement Disorder Society ‚ÌŒö”FƒvƒƒOƒ‰ƒ€‚Å‚·B

East Asian Neurology Forum

Keynote Session

5ŒŽ19“úi–Øj 13:10`14:40@3A‰ïêi3†ŠÙ3ŠK‘Û‰ï‹cŽºj

À’·F
ЯԼ@~iDepartment of Neurology, University of Iowa, USAj
 
‚‹´@—Ç•ãi‹ž“s‘åŠw_Œo“à‰Èj
EA-K-1
Message from the WCN to the East Asian Neurology

Mostafa El Alaoui FarisiPresident of the 20th World Congress of Neurology, Marrakesh, 2011, Moroccoj

EA-K-2
Role of the CSN in East Asia

Liying CuiiFormer President of the Chinese Society of Neurology, Chinaj

EA-K-3
Role of the KNA in East Asia

Beom S. JeoniInternational Delegate of the Korean Neurological Association, Koreaj

EA-K-4
Role of the JSN in East Asia

…àV@‰p—mi“ú–{_ŒoŠw‰ï‘ã•\—Ž–C“Œ‹žˆã‰ÈŽ•‰È‘åŠw‘åŠw‰@”]_Œo•a‘ÔŠw•ª–ìj

EA-K-5
Žw’è”­Œ¾

Š@—´™Zi¢ŠE_ŒoŠw˜A–¿—Ž–C“¿“‡‘åŠw_Œo“à‰Èj

5ŒŽ19“úi–Øj 14:40`16:45@3A‰ïêi3†ŠÙ3ŠK‘Û‰ï‹cŽºj

À’·F
ŽR–{@Œõ—˜i쌧—§’†‰›•a‰@_Œo“à‰Èj
 
Beom S. JeoniSeoul National University Hospital, Koreaj
Žw’è”­Œ¾
Accelerating the Cure for Parkinsonfs Disease:MJFF Mission and Funding Philosophy

Mark FrasieriResearch Programs, Michael J Fox Foundation for Parkinsonfs Research, USAj

ParkinsonismFup-to-date

EA-1-1
Neuroimaging and Diagnosis of Parkinsonism

Chong S. LeeiASAN Medical Center, Koreaj

EA-1-2
Treatment of early Parkinsonfs disease

Louis TaniNational Neuroscience Institute, Singaporej

EA-1-3
Treatment of advanced Parkinsonfs disease

Shu-Leong HoiUniversity of Hong Kong Queen Mary Hospital, Hong Kongj

EA-1-4
Non-motor feature in Parkinsonfs disease

‘O“c@“N–çiH“cŒ§—§”]ŒŒŠÇŒ¤‹†ƒZƒ“ƒ^[_Œo“à‰ÈŠwŒ¤‹†•”j

EA-1-5
Genetics of Parkinsonfs disease in Asia

Chin-Song LuiChang Gung Medical Center at Linkou, Taiwanj

ƒy[ƒWƒgƒbƒv‚Ö↑

the Movement Disorder Society
  • East Asian Neurology Forum: Poster Session ‚ÍThe Movement Disorder Society ‚ÌŒö”FƒvƒƒOƒ‰ƒ€‚Å‚·B

East Asian Neurology Forum: Poster Session

5ŒŽ18“úi…j 16:45`17:30iŽ©—R“¢˜_j/17:30`18:30iƒ|ƒXƒ^[”­•\j
1Eiƒ|ƒXƒ^[‘æ1j‰ïêi1†ŠÙ1ŠKƒCƒxƒ“ƒgƒz[ƒ‹j

À’·F
‘åŒF@‘×”Vi‡“V“°‘åŠwˆãŠw•”•‘®Ã‰ª•a‰@”]_Œo“à‰Èj
EP-A-1
The effect of IV amantadine on freezing of gaitifogjresistant to dopaminergic therapy

Young Eun KimiDepartments of Neurology and Movement Disorder Center, College of Medicine, Seoul National Universityj

EP-A-2
Detecting falls and freezing with motion recorder in Parkinsonfs disease patients under daily life condition

Yasuyuki OkumaiDepartment of Neurology, Juntendo University Shizuoka Hospitalj

EP-A-3
Relative significance of SCA2, SCA3 and SCA17 in Korean patients with parkinsonism

Ji Young YuniDepartment of Neurology, Seoul National University Hospitalj

EP-A-4
First case with X-linked dystonia-parkinsonismiXDP: DYT-3eLubagfjimproved by bilateral pallidum stimulation in Japan

Katsuo KimuraiDepartment of Neurology, Tokyo Metropolitan Neurological Hospitalj

EP-A-5
Role of serotonin receptor 2A gene variants in the impulsive compulsive behaviors in PD

Jee-Young LeeiDepartment of Neurology, College of Medicine, Seoul National University Boramae Hospital; Parkinson Study Group, Seoul National University Hospitalj

EP-A-6
Improvement of pathological gambling following subthalamic nucleus stimulation for Parkinsonfs disease

Hidemoto SaikiiDepartment of Neurology, Kitano Hospital, The Tazuke Kofukai Medical Institutej

EP-A-7
The Benefit of STN|DBS on Pain in Parkinson Disease: A 2|Year Follow|Up Study

Han-Joon KimiDepartments of Neurology and Movement Disorder Center, and Neuroscience Research Institute, BK21, College of Medicine, Seoul National University Hospital, Seoul, Korea; Parkinson Disease Study Group, Seoul National University Hospital, Seoul, Koreaj

À’·F
•ž•”@MFi‡“V“°‘åŠwˆãŠw•”•‘®‡“V“°ˆã‰@”]_Œo“à‰Èj
EP-B-1
Compound heterozygous rearrangements of parkin in early-onset parkinsonism

Yuanzhe LiiResearch Institute for Diseases of Old Age, Graduate School of Medicine, Juntendo Universityj

EP-B-2
Treatment of AD model mice with TAPIR-like monoclonal antibody 3.4A10

Haifeng JiniResearch Institute for Diseases of Old Age, Juntendo University Graduate School of Medicine; Department of Diagnosis, Prevention and Treatment of Dementia, Juntendo University Graduate School of Medicinej

EP-B-3
The role of dynactin-1 in autophagy: a regulator for autophagosome-lysosome fusion

Zhe HuangiDepartment of Neurology, Nagoya University Graduate School of Medicinej

EP-B-4
Prospective observations of cognitive function and plasma homocysteine level in Parkinsonfs disease

Tetsuya MaedaiDepartment of Neurology, Research Institute for Brain and Blood Vessels Akitaj

EP-B-5
Hsp90 inhibitors ameliorates polyglutamine-mediated motor dysfunction in SBMA models

Qiang QiangiDepartment of Neurology, Nagoya University Graduate School of Medicinej

EP-B-6
Clinical correlates of anterior flexion of the thoracolumbar spine in patients with Parkinsonfs disease

Kenichi KashiharaiDepartment of Neurology, Okayama Kyokuto Hospitalj

ƒy[ƒWƒgƒbƒv‚Ö↑

ƒVƒ“ƒ|ƒWƒEƒ€

ƒVƒ“ƒ|ƒWƒEƒ€1
BAD ‚Í‚Ç‚¤’è‹`‚µC‘Ήž‚·‚é‚©GŠe‘‚Ìl‚¦•û

5ŒŽ19“úi–Øj 13:15`14:45@1B‰ïêi1†ŠÙ3ŠK‰ï‹cŽº131{132j

À’·F
ŽÂŒ´@Kli‘‰ÆŒö–±ˆõ‹¤Ï‘g‡˜A‡‰ï—§ì•a‰@_Œo“à‰Èj
 
’I‹´@‹I•vié‹Êˆã‰È‘åŠw‘Ûˆã—ÃZƒ“ƒ^[”]‘²’†“à‰Èj
SY-01-1
‰ä‚ª‘‚É‚¨‚¯‚éBAD ‚ÌŒ»óiJ|BAD Registry ‚̉ðÍ‚©‚çj

¯–ì@°•Fi“Œ‹ž“s϶‰ï’†‰›•a‰@_Œo“à‰Èj

SY-01-2
Branch atheromatous disease:an important cause of small subcortical infarction in Asia

Jong Sung KimiMedical college, University of Ulsan; Department of Neurology, Asan Medical Center; Stroke Center, Asan Medical Center, Koreaj

SY-01-3
Branch atheromatous disease:prognosis and management. The SPS3 experience

Oscar BenaventeiDivision of Neurology, University of British Columbia, Canadaj

ƒVƒ“ƒ|ƒWƒEƒ€2
ƒAƒ‹ƒcƒnƒCƒ}[•a‚Ì•ªŽqŽ¡—Ãí—ªFV‚µ‚¢Ž‹“_‚ð‹‚ß‚Ä

5ŒŽ19“úi–Øj 13:15`14:45@1C‰ïêi1†ŠÙ3ŠK‰ï‹cŽº133{134j

À’·F
‘唪–Ø@•Û­i‹ãB‘åŠw‘åŠw‰@ˆãŠwŒ¤‹†‰@”]Œ¤_Œo“à‰Èj
 
Œ´@‰p•vi²‰ê‘åŠwˆãŠw•”_Œo“à‰Èj
SY-02-1
×–E“àƒAƒ~ƒƒCƒhƒÀ‚¨‚æ‚ÑŽ_‰»ƒXƒgƒŒƒX‚ð•W“I‚Æ‚·‚鎡—ÖòFƒAƒ|ƒ‚ƒ‹ƒtƒBƒ“

‘唪–Ø@•Û­i‹ãB‘åŠw‘åŠw‰@ˆãŠwŒ¤‹†‰@”]Œ¤_Œo“à‰Èj

SY-02-2
ƒAƒ‹ƒcƒnƒCƒ}[•a‚ÆŠ¿•ûŽ¡—Ã

Œ´@‰p•vi²‰ê‘åŠwˆãŠw•”_Œo“à‰Èj

SY-02-3
•ªŽqƒVƒƒƒyƒƒ“—U“±Ü‚̃Aƒ‹ƒcƒnƒCƒ}[•aŽ¡—Âւ̉ž—p

H“¡@‹ªi‘åã‘åŠw‘åŠw‰@ˆãŠwŒnŒ¤‹†‰È¸_ˆãŠw‹³Žºj

SY-02-4
ƒAƒ~ƒƒCƒhƒÀ‚Ì“Å«ƒ^[ƒ“\‘¢‚ð”FŽ¯‚·‚éR‘Ì‚ÌŠJ”­

“ü]@ˆê_i‹ž“s‘åŠw”_ŠwŒ¤‹†‰ÈH•i¶•¨‰ÈŠwêUj

ƒVƒ“ƒ|ƒWƒEƒ€3
’E‘«Ž¾Š³‚É‚¨‚¯‚éƒOƒŠƒAŠÔ‚¨‚æ‚уOƒŠƒAEƒjƒ…[ƒƒ“ŠÔ‘ŠŒÝì—p‚Ì”j’]

5ŒŽ19“úi–Øj 13:15`14:45@2C‰ïêi2†ŠÙ2ŠK‰ï‹cŽº222{223j

À’·F
‹g—Ç@ˆêi‹ãB‘åŠw_Œo“à‰Èj
 
Žà‘º@–¾¶i–¼ŒÃ‰®‘åŠwŠÂ‹«ˆãŠwŒ¤‹†Š_Œo–Ɖu•ª–ìj
SY-03-1
_Œo‰ÈŠw‚©‚猩‚½’E‘«Ž¾Š³‚É‚¨‚¯‚é–Ɖu×–EEƒOƒŠƒAEƒjƒ…[ƒƒ“ŠÔ‘ŠŒÝì—p‚̈Ùí

…–ì@“N–çi–¼ŒÃ‰®‘åŠwŠÂ‹«ˆãŠwŒ¤‹†Š_Œo–Ɖu•ª–ìj

SY-03-2
MS/NMO‚̃‚ƒfƒ‹‚©‚ç‚Ý‚½’E‘«Ž¾Š³‚É‚¨‚¯‚é–Ɖu×–EEƒOƒŠƒAEƒjƒ…[ƒƒ“ŠÔ‘ŠŒÝì—p‚̈Ùí

’†’Ò@—TŽii‘åã‘åŠw_Œo“à‰Èj

SY-03-3
Ž‹_ŒoÒ‘‰ŠC‘½”­«d‰»ÇCBalo•a‚É‚¨‚¯‚éƒAƒXƒgƒƒTƒCƒgáŠQ‚Ì“Á’¥

¼‰º@‘ñ–çi‹ãB‘åŠw—Õ°_Œo–ƉuŠwj

ƒVƒ“ƒ|ƒWƒEƒ€4
_Œo“à‰È—̈æ‚É‚¨‚¯‚é‘O•ûŒü“IƒRƒz[ƒgŒ¤‹†‚©‚猩‚¦‚Ä‚«‚½‚à‚Ì

5ŒŽ19“úi–Øj 13:15`14:45@2D‰ïêi2†ŠÙ2ŠK‰ï‹cŽº224j

À’·F
•ô¼@ˆê•vi‘—§zŠÂŠí•aŒ¤‹†ƒZƒ“ƒ^[j
 
ŽáŽR@‹gOiº˜a‘åŠw–¼—_‹³Žöj
SY-04-1
‹ØƒWƒXƒgƒƒtƒB[ƒŒƒWƒXƒgƒŠ[iRemudyjGŠ³ŽÒ‚ÌŽ©”­“I“o˜^ƒVƒXƒeƒ€\’z‚ÆŠCŠO‚Ƃ̘AŒg

’†‘º@Ž¡‰ëi‘—§¸_E_Œoˆã—ÃŒ¤‹†ƒZƒ“ƒ^[_Œo“à‰Èj

SY-04-2
JaCALSGALS‚ÌisC—\Œã‹K’èˆöŽq

”M“c@’¼Ž÷i–¼ŒÃ‰®‘åŠw_Œo“à‰Èj

SY-04-3
”F’mǂ̃Rƒz[ƒgŒ¤‹†F‹vŽR’¬Œ¤‹†

´Œ´@—Ti‹ãB‘åŠwŠÂ‹«ˆãŠw•ª–ìj

SY-04-4
JAMSACFMSA‚ɑ΂·‚édisease|modifying therapyŽÀŒ»‚Ì‚½‚ß‚Ì—Õ°Ž¡Œ±ƒfƒUƒCƒ“

Žsì@–í¶ŽqiJAMSACiJapan MSA research consortiumjC“Œ‹ž‘åŠw_Œo“à‰Èj

ƒVƒ“ƒ|ƒWƒEƒ€5
‹ØƒWƒXƒgƒƒtƒB[V‹KŽ¡—Ö@ŠJ”­‚ÌÅ‘Oü

5ŒŽ19“úi–Øj 13:15`14:45@2E‰ïêi2†ŠÙ3ŠK‰ï‹cŽº232{233j

À’·F
»“c@–FGiìèˆã‰È‘åŠw_Œo“à‰ÈŠwj
 
¼‘º@Šìˆê˜Yi’é‹ž‘åŠwˆãŠw•”_Œo“à‰Èj
SY-05-1
ƒfƒ…ƒVƒFƒ“ƒkŒ^‚ɑ΂·‚éƒGƒLƒ\ƒ“ƒXƒLƒbƒvŽ¡—Ã

•“c@Lˆêi‘—§¸_E_Œoˆã—ÃŒ¤‹†ƒZƒ“ƒ^[ˆâ“`ŽqŽ¾Š³Ž¡—ÃŒ¤‹†•”j

SY-05-2
•ŸŽRŒ^‹ØƒWƒXƒgƒƒtƒB[‚ÌV‚½‚È•a‘ÔEŽ¡—Ãí—ª

ŒË“c@’BŽji_ŒË‘åŠw_Œo“à‰Èj

SY-05-3
Large‚É‚æ‚郿|ƒWƒXƒgƒƒOƒŠƒJƒmƒpƒ`[‚ɑ΂·‚鎡—Ö@‚ÌŠJ”­

Ä“¡@Žj–¾i’é‹ž‘åŠw_Œo“à‰Èj

SY-05-4
œŠi‹ØĶŽ¡—Ã

‘åàV@—Tiìèˆã‰È‘åŠw•‘®•a‰@_Œo“à‰Èj

ƒVƒ“ƒ|ƒWƒEƒ€6
Brain|machine interface‚Í‚Ç‚±‚܂ʼn”\‚©H

5ŒŽ19“úi–Øj 13:15`14:45@2F‰ïêi2†ŠÙ3ŠK‰ï‹cŽº234j

À’·F
•ÐŽR@‘טNi“ú–{ˆã‰È‘åŠw_ŒoEt‘ŸEäPŒ´•aƒŠƒEƒ}ƒ`“à‰È•”–åj
 
–{“c@Šwi‘—§¸_E_Œoˆã—ÃŒ¤‹†ƒZƒ“ƒ^[j
SY-06-1
Ò‘‘¹Œã‚Ì‹@”\‰ñ•œ‹@˜‚̉𖾂Ƌ@”\‚ð•â‚¤lH_ŒoÚ‘±

¼‘º@K’ji¶—ŠwŒ¤‹†Š”F’ms“®”­’B‹@\Œ¤‹†•”–åj

SY-06-2
Real|time NIRS‚É‚æ‚éƒjƒ…[ƒƒtƒB[ƒhƒoƒbƒN‚ð—p‚¢‚½_ŒoƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“

ŽOŒ´@‰ëŽjiX”V‹{•a‰@_ŒoƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“Œ¤‹†•”E_Œo“à‰Èj

SY-06-3
_ŒoƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“‚É‚¨‚¯‚é”ñNP“IBrain-machine interface‚̉”\«

‹ê@ˆêiŒcœä‹`m‘åŠw—HŠw•”¶–½î•ñŠw‰Èj

ƒVƒ“ƒ|ƒWƒEƒ€7
Atypical types of dementia”ñ“TŒ^”F’mÇ

5ŒŽ19“úi–Øj 8:30`10:30@3A‰ïêi3†ŠÙ3ŠK‘Û‰ï‹cŽºj

À’·F
Šâ“c@~i“Œ‹ž‘åŠwˆãŠwŒnŒ¤‹†‰È_Œo“à‰Èj
 
‰Í‘º@–žiº˜a‘åŠw“à‰ÈŠwuÀ_Œo“à‰ÈŠw•”–åj
SY-07-1
Dementia‚Ì•ªŽq•a‘ÔFEpigeneticsŒ¤‹†‚©‚ç

Šâ“c@~i“Œ‹ž‘åŠwˆãŠwŒnŒ¤‹†‰È_Œo“à‰Èj

SY-07-2
”ñ“TŒ^”F’mÇ‚Ö‚Ì—Õ°“IƒAƒvƒ[ƒ`

—é–Ø@‹§ŽqiŽRŒ`‘åŠw‘åŠw‰@ˆãŠwŒnŒ¤‹†‰È‚ŽŸ”]‹@”\áŠQŠwj

SY-07-3
”玿«‹U«‹…–ƒáƒ‚É‚æ‚é”­˜báŠQ‚Å”­Ç‚·‚é_Œo•Ï«Ž¾Š³

ÎŒ´@Œ’Žiiº˜a‘åŠw•a‰@_Œo“à‰Èj

SY-07-4
Dementia with motor neuron disease

Michael J. StrongiDepartment of Clinical Neurological Sciences, The Schulich School of Medicine & Dentistry, The University of Western Ontario, Canadaj

ƒVƒ“ƒ|ƒWƒEƒ€8
’É‚Ý‚ÌÅV‚Ì•a‘Ô‚ÆŽ¡—Ã

5ŒŽ19“úi–Øj 13:15`14:45@4A‰ïêi4†ŠÙ1ŠK”’’¹ƒz[ƒ‹i–kjj

À’·F
‹“c@‹Giˆ¤’mˆã‰È‘åŠwŠwÛ“I’ɂ݃Zƒ“ƒ^[j
 
”nê@³”ViÂXŒ§—§’†‰›•a‰@_Œo“à‰Èj
SY-08-1
Neuropathic pain-definition, mechanisms diagnosis and management

Ralf BaroniDivision of Neurological Pain Research and Therapy, Department of Neurologie, Univesitäetsklinikum Schleswig-Holstein, Germanyj

SY-08-2
Ò‘‘“àŽîá‡pŒã‚ÌÒ‘áŠQ«áu’É‚Ì•a‘Ô

’†‘º@‰ë–çiŒcœä‹`m‘åŠwˆãŠw•”®Œ`ŠO‰Èj

SY-08-3
_ŒoáŠQ«áu’É‚Ì•Û‘¶“IŽ¡—Ã

‹“c@‹Giˆ¤’mˆã‰È‘åŠwŠwÛ“I’ɂ݃Zƒ“ƒ^[j

ƒVƒ“ƒ|ƒWƒEƒ€9
”玿‰º«ŒŒŠÇáŠQ‚Ì•a‘Ô‚ÆŽ¡—Ã

5ŒŽ19“úi–Øj 13:15`14:45@4B‰ïêi4†ŠÙ1ŠK”’’¹ƒz[ƒ‹i“ìjj

À’·F
“à–ì@½iŒF–{‘åŠw‘åŠw‰@¶–½‰ÈŠwŒ¤‹†•”_Œo“à‰ÈŠw•ª–ìj
 
•y–{@G˜aiŽOd‘åŠw_Œo•a‘Ô“à‰ÈŠw•ª–ìj
SY-09-1
”玿‰ºŒŒŠÇ«”F’mÇF”F’mÇŽ¾Š³‚É‚¨‚¯‚éˆÊ’u‚¯

•y–{@G˜aiŽOd‘åŠw_Œo•a‘Ô“à‰ÈŠw•ª–ìj

SY-09-2
TGF|ƒÀƒtƒ@ƒ~ƒŠ[ƒVƒOƒiƒ‹‚̈Ùí‚Æ”]¬ŒŒŠÇ•a|CARASIL‚Ì•ªŽq•a‘Ԃ̉ðÍ‚©‚ç

¬–쎛@—iVŠƒ‘åŠw”]Œ¤‹†Š•‘®¶–½‰ÈŠwƒŠƒ\[ƒXŒ¤‹†ƒZƒ“ƒ^[”]Ž¾Š³ƒŠƒ\[ƒX‰ðÍ•”–åj

SY-09-3
”玿‰º«ŒŒŠÇáŠQ‚Ì•a‘Ô‚ÆŽ¡—Ã\CADASIL

“à–ì@½iŒF–{‘åŠw‘åŠw‰@¶–½‰ÈŠwŒ¤‹†•”_Œo“à‰ÈŠw•ª–ìj

ƒVƒ“ƒ|ƒWƒEƒ€10
—Õ°‚ÆŒ¤‹†‚ɖ𗧂ÂÅV‚ÌMRIŠw

5ŒŽ19“úi–Øj 13:15`14:45@4C‰ïêi4†ŠÙ3ŠK‰ï‹cŽº432j

À’·F
–Ø@–ÎŽ÷i‡“V“°‘åŠw•úŽËüˆãŠwuÀj
 
X@‰x˜Ni“Œ–k‘åŠw‘åŠw‰@ˆãŠwŒnŒ¤‹†‰È‚ŽŸ”]‹@”\áŠQŠw•ª–ìj
SY-10-1
MRI‚ÅŒ©‚¦‚é‚à‚ÌG3.0T‚Æ1.5T‚Ƃ̑Δä

ŽO–Ø@K—Yi‘åãŽs—§‘åŠw•úŽËü‰Èj

SY-10-2
_Œo“à‰È—̈æ‚É‚¨‚¯‚éMRI‚ð—p‚¢‚½—Õ°Œ¤‹†|1–‡‚̉摜‚ð‚Ç‚¤•]‰¿‚·‚é‚©|

ˆÉ“¡@²ˆêiç—t‘åŠw‘åŠw‰@ˆãŠwŒ¤‹†‰@ˆãŠw‹³ˆçŒ¤‹†Žºj

SY-10-3
ŠgŽUMRI‚Ì—Õ°‰ž—p

–Ø@–ÎŽ÷i‡“V“°‘åŠw•úŽËüˆãŠwuÀj

ƒVƒ“ƒ|ƒWƒEƒ€11
_Œo“à‰Èˆã‚̃ŠƒNƒ‹[ƒg‚ÉŒq‚°‚é–¢—ˆ‚Ö‚Ì’ñŒ¾

5ŒŽ19“úi–Øj 14:45`16:45@2C‰ïêi2†ŠÙ2ŠK‰ï‹cŽº222{223j

À’·F
“¹—E@Šwiˆ¤’mˆã‰È‘åŠw_Œo“à‰Èj
 
‰¡“c@—²“¿i“Œ‹žˆã‰ÈŽ•‰È‘åŠw_Œo“à‰Èj

Keynote Lecture  Attracting the best and brightest to careers in neurology

Donald H. SilberbergiUniversity of Pennsylvania, USAj

SY-11-1
Medical Neurology/Critical Neurology

Š¡“c@“T¶i_ŒË‘åŠwˆãŠw•”•‘®•a‰@_Œo“à‰Èj

SY-11-2
Expert/Neurologist `—Õ°

“ŒŠC—Ñ@Š²•viO‘O‘åŠw‘åŠw‰@ˆãŠwŒ¤‹†‰È”]_Œo“à‰ÈŠwj

SY-11-3
Disease-oriented Neuroscience Researcher

–]ŒŽ@GŽ÷i–k—¢‘åŠw_Œo“à‰ÈŠwj

ƒVƒ“ƒ|ƒWƒEƒ€12
‹Ø‰ŠŒ¤‹†Å‹ß‚Ìi•à

5ŒŽ19“úi–Øj 14:45`16:45@2D‰ïêi2†ŠÙ2ŠK‰ï‹cŽº224j

À’·F
–Ø@³Žui“Œ–k‘åŠw‘åŠw‰@ˆãŠwŒnŒ¤‹†‰È_Œo“à‰Èj
 
¼–ì@ˆêŽOi‘—§¸_E_Œoˆã—ÃŒ¤‹†ƒZƒ“ƒ^[_ŒoŒ¤‹†ŠŽ¾•aŒ¤‹†‘æˆê•”j
SY-12-1
‹Ø‰ŠŠÖ˜AŽ©ŒÈR‘Ì

ŒK–¼@³—²iŒcœä‹`m‘åŠwƒŠƒEƒ}ƒ`“à‰Èj

SY-12-2
RSRPR‘Ì—z«ƒ~ƒIƒpƒ`[

—é–Ø@d–¾iŒcœä‹`m‘åŠw•a‰@_Œo“à‰Èj

SY-12-3
••“ü‘̋؉Š‚Ì•a‘Ô‚Æ•p“x

—é–Ø@’¼‹Pi“Œ–k‘åŠw•a‰@_Œo“à‰Èj

SY-12-4
‹Ø‰ŠŽ¡—ÂÌÅ‘Oü

´…@i“Œ‹ž‘åŠw•a‰@_Œo“à‰Èj

ƒVƒ“ƒ|ƒWƒEƒ€13
ŽŸ¢‘ãƒV[ƒPƒ“ƒT[‚É‚æ‚é_ŒoŽ¾Š³‚̉ð–¾

5ŒŽ19“úi–Øj 14:45`16:45@2E‰ïêi2†ŠÙ3ŠK‰ï‹cŽº232{233j

À’·F
’Ò@ÈŽŸi“Œ‹ž‘åŠw_Œo“à‰Èj
 
ŒË“c@’BŽji_ŒË‘åŠw‘åŠw‰@ˆãŠwŒ¤‹†‰È_Œo“à‰ÈŠw•ªŽq”]‰ÈŠwj
SY-13-1
ƒp[ƒ\ƒiƒ‹ƒQƒmƒ€Œ¤‹†‚̃I[ƒo[ƒrƒ…[

ŒË“c@’BŽji_ŒË‘åŠw‘åŠw‰@ˆãŠwŒ¤‹†‰È_Œo“à‰ÈŠw•ªŽq”]‰ÈŠwj

’Ò@ÈŽŸi“Œ‹ž‘åŠw_Œo“à‰Èj

SY-13-2
ƒp[ƒ\ƒiƒ‹ƒQƒmƒ€‚Ìî•ñ‰ðÍFŒ»ó‚Ì®—‚Æ“W–]

X‰º@^ˆêi“Œ‹ž‘åŠwî•ñ¶–½‰ÈŠwêUj

SY-13-3
ˆâ“`«_ŒoŽ¾Š³‚ÌŒ¤‹†|Posterior column ataxia with retinitis pigmentosa|

ΉY@_”Vi“Œ‹ž‘åŠw_Œo“à‰Èj

SY-13-4
ŒÇ”­«Ž¾Š³‚ÌŒ¤‹†|ƒp[ƒLƒ“ƒ\ƒ“•a

ŽOˆä@ƒi“Œ‹ž‘åŠw•a‰@_Œo“à‰Èj

SY-13-5
ƒp[ƒ\ƒiƒ‹ƒQƒmƒ€Œ¤‹†‚Ì—Ï—“I‰Û‘è

‰Á“¡@˜ali‹ž“s‘åŠwƒQƒmƒ€ELSIƒ†ƒjƒbƒgj

ƒVƒ“ƒ|ƒWƒEƒ€14
_Œo•Ï«‚ð‚Ç‚¤l‚¦‚é‚©H•a‘Ô—‰ð‚ÉŽŠ‚éÅ‹ß‚Ìi•à

5ŒŽ19“úi–Øj 14:45`16:45@2F‰ïêi2†ŠÙ3ŠK‰ï‹cŽº234j

À’·F
‘«—§@O–¾i–¼ŒÃ‰®‘åŠw_Œo“à‰Èj
 
ŠÑ–¼@Msi—‰»ŠwŒ¤‹†Š\‘¢_Œo•a—Œ¤‹†ƒ`[ƒ€j
SY-14-1
‹ÃW‘ÌŒ`¬‚©‚ç‚Ý‚½_Œo•Ï«‹@˜

ŠÑ–¼@Msi—‰»ŠwŒ¤‹†Š\‘¢_Œo•a—Œ¤‹†ƒ`[ƒ€j

SY-14-2
DNA‘¹C•œ‚©‚ç‚Ý‚½_Œo•Ï«‹@˜

‰ªàV@‹Ïi“Œ‹žˆã‰ÈŽ•‰È‘åŠwj

SY-14-3
TGF|ƒÀƒVƒOƒiƒ‹‚©‚ç‚Ý‚½_Œo•Ï«‹@˜

Ÿ–ì@‰ë‰›i–¼ŒÃ‰®‘åŠw_Œo“à‰Èj

SY-14-4
Žá”N«ƒp[ƒLƒ“ƒ\ƒ“•a‚Ì•a‘Ô‰ð–¾FƒCƒ“ƒXƒŠƒ“ŠJŒû‹@\‚©‚ç‚»‚Ì•aˆö‚É”—‚é

•ž•”@MFi‡“V“°‘åŠwˆãŠw•”•‘®‡“V“°ˆã‰@”]_Œo“à‰Èj

SY-14-5
ƒ~ƒgƒRƒ“ƒhƒŠƒA‚©‚猩‚½_Œo•Ï«‹@˜\ƒp[ƒLƒ“ƒ\ƒ“•a‚ð—á‚É\

¼“c@Œ›”Vi“Œ‹ž“sˆãŠw‘‡Œ¤‹†Š’`”’Ž¿‘ãŽÓŒ¤‹†Žºj

ƒVƒ“ƒ|ƒWƒEƒ€15
ÅV‚Ì‚Ä‚ñ‚©‚ñ‚Ì•a‘Ô‚ÆŽ¡—Ãi‹¤ÃF“ú–{‚Ä‚ñ‚©‚ñŠw‰ïj

5ŒŽ19“úi–Øj 14:45`16:45@4A‰ïêi4†ŠÙ1ŠK”’’¹ƒz[ƒ‹i–kjj

À’·F
Œ“Žq@’¼iO‘O‘åŠw‘åŠw‰@ˆãŠwŒ¤‹†‰È_Œo¸_ˆãŠwuÀj
 
’Ò@’åriŽY‹Æˆã‰È‘åŠw_Œo“à‰Èj
SY-15-1
‚Ä‚ñ‚©‚ñ‚̃LƒƒƒŠ[ƒI[ƒo[Š³ŽÒ‚Ì–â‘è

‘å’Ë@èñŽqi‰ªŽR‘åŠw•a‰@¬Ž™_Œo‰Èj

SY-15-2
‚Ä‚ñ‚©‚ñ‚Ì–À‘–_ŒoŽhŒƒ—Ö@

ì‡@Œª‰îi“Œ‹ž‘åŠw‘åŠw‰@ˆãŠwŒnŒ¤‹†‰È”]_ŒoŠO‰Èj

SY-15-3
‚Ä‚ñ‚©‚ñŒ¤‹†‚ÌÅ‘Oü

’r“c@º•vi‹ž“s‘åŠw•a‰@_Œo“à‰Èj

SY-15-4
‚Ä‚ñ‚©‚ñŽ¡—ÂÌÅ‘Oü

d“¡@Š°Žji‹ãB‘åŠw•a‰@_Œo“à‰Èj

ƒVƒ“ƒ|ƒWƒEƒ€16
S–[ד®Š³ŽÒ‚ÌR‹ÃŒÅ—Ö@\VŽž‘ã‚ւ̑Ήž\

5ŒŽ19“úi–Øj 14:45`16:45@4B‰ïêi4†ŠÙ1ŠK”’’¹ƒz[ƒ‹i“ìjj

À’·F
“àŽR@^ˆê˜Yi“Œ‹ž—Žqˆã‰È‘åŠw_Œo“à‰Èj
 
–îâ@³Oi‘—§•a‰@‹@\‹ãBˆã—ÃZƒ“ƒ^[”]ŒŒŠÇE_Œo“à‰Èj
SY-16-1
S–[ד®‚ÌVƒKƒCƒhƒ‰ƒCƒ“‚Æ“úíf—Âւ̑Ήž

ŽR‰º@•ŽuiS‘ŸŒŒŠÇŒ¤‹†ŠzŠÂŠí“à‰Èj

SY-16-2
S–[ד®‚Æ”]ÇðÇF‹}«ŠúŽ¡—Â̎ÀÛ‚Æ–â‘è“_

–îâ@³Oi‘—§•a‰@‹@\‹ãBˆã—ÃZƒ“ƒ^[”]ŒŒŠÇE_Œo“à‰Èj

SY-16-3
ƒgƒƒ“ƒrƒ“‘jŠQ–ò‚Ö‚ÌŠú‘Ò‚Æ–â‘è“_

“àŽR@^ˆê˜Yi“Œ‹ž—Žqˆã‰È‘åŠw_Œo“à‰Èj

SY-16-4
Xa‘jŠQ–ò‚ÌÅV‚̃Gƒrƒfƒ“ƒX‚Æ“W–]

’·”ö@‹B•Fi“Œ‹ž—Žqˆã‰È‘åŠw_Œo“à‰Èj

ƒVƒ“ƒ|ƒWƒEƒ€17
“«––½_ŒoŽ¾Š³‚ÌŽ¡—Ãí—ª

5ŒŽ19“úi–Øj 14:45`16:45@4C‰ïêi4†ŠÙ3ŠK‰ï‹cŽº432j

À’·F
_“c@—²iŽRŒû‘åŠw‘åŠw‰@ˆãŠwŒnŒ¤‹†‰È_Œo“à‰Èj
 
’†ì@³–@i‹ž“s•{—§ˆã‰È‘åŠw_Œo“à‰ÈŠwj

Keynote Lecture  Perspectives in refractory diabetic and amyloid small-fiber neuropathy

Gerard SaidiDepartment of Neurology Hospital de la Salpetriere, Francej

SY-17-1
–«‰ŠÇ«’E‘«‘½”­ªƒjƒ…[ƒƒpƒ`[‚ÌŽ¡—Ô½‰ž«

”Ñ“‡@³”Ži–¼ŒÃ‰®‘åŠw_Œo“à‰Èj

SY-17-2
ƒVƒƒƒ‹ƒR[Eƒ}ƒŠ[EƒgƒD[ƒX•a‚ÌŽ¡—Ãí—ª

’†ì@³–@i‹ž“s•{—§ˆã‰È‘åŠw_Œo“à‰ÈŠwj

SY-17-3
ƒNƒƒEE[£ÇŒóŒQ

ŒKŒ´@‘iç—t‘åŠw•a‰@_Œo“à‰Èj

SY-17-4
ŒŒ‰t_ŒoŠÖ–å‚ðƒ^[ƒQƒbƒg‚Æ‚µ‚½Ž¡—Ãí—ª

_“c@—²iŽRŒû‘åŠw•a‰@_Œo“à‰Èj

ƒVƒ“ƒ|ƒWƒEƒ€18
_Œo“ï•aŠ³ŽÒ‚Ì‘‡“IŽx‰‡

5ŒŽ20“úi‹àj 13:15`14:45@1B‰ïêi1†ŠÙ3ŠK‰ï‹cŽº131{132j

À’·F
Ž…ŽR@‘×li‘—§¸_E_Œoˆã—ÃŒ¤‹†ƒZƒ“ƒ^[j
 
¡ˆä@®Žui‘—§•a‰@‹@\‹{é•a‰@_Œo“à‰Èj
SY-18-1
“ï•aƒlƒbƒgƒ[ƒN‚Æ“ï•aŠ³ŽÒŽx‰‡

‹g—Ç@ˆêi‹ãB‘åŠw_Œo“à‰Èj

SY-18-2
“ï•aŠ³ŽÒ‚ÌQOL

¬X@“N•vi‘—§•a‰@‹@\” ª•a‰@j

SY-18-3
Ý‘î_Œo“ï•aŠ³ŽÒ‚ÌЊQŽžŽx‰‡Œv‰æ

¼àV@³–LiVŠƒ‘åŠw•a‰@”]Œ¤‹†Š—Õ°_Œo‰ÈŠw•”–å_Œo“à‰ÈŠw•ª–ìj

SY-18-4
u“ï•aŠ³ŽÒ‚Ìg‚¶‚è‚Âh‚ðˆç‚ÞŽx‰‡‚Ì\’z‚ÉŒü‚¯‚ÄvŒ¤‹†”ǂ̬‰Ê‚Æ“Œ–kEŠÖ“Œ‘åkЂ̌oŒ±‚𓥂܂¦‚Ä

¡ˆä@®Žui‘—§•a‰@‹@\‹{é•a‰@_Œo“à‰Èj

ƒVƒ“ƒ|ƒWƒEƒ€19
ƒOƒŠƒA×–E‚Æ_ŒoŽ¾Š³

5ŒŽ20“úi‹àj 13:15`14:45@1C‰ïêi1†ŠÙ3ŠK‰ï‹cŽº133{134j

À’·F
Žà‘º@–¾¶i–¼ŒÃ‰®‘åŠwŠÂ‹«ˆãŠwŒ¤‹†Š_Œo–Ɖu•ª–ìj
 
¼ˆä@^i‹à‘òˆã‰È‘åŠw_Œo“à‰Èj
SY-19-1
ƒAƒ‹ƒcƒnƒCƒ}[•a‚ƃ~ƒNƒƒOƒŠƒA

”óŒû@^li•úŽËüˆãŠw‘‡Œ¤‹†Š•ªŽqƒCƒ[ƒWƒ“ƒOŒ¤‹†ƒZƒ“ƒ^[j

SY-19-2
”]‹•ŒŒ‚ƃAƒXƒgƒƒTƒCƒg

‚‹´@œÄˆêiŒcœä‹`m‘åŠw_Œo“à‰Èj

SY-19-3
’E‘‚ƃIƒŠƒSƒfƒ“ƒhƒƒTƒCƒg

ˆÉ“¡@‚siUniversity of California Davis/Shriners Hospitals for Children Northern California, Department of Neurology, USAj

ƒVƒ“ƒ|ƒWƒEƒ€20
“«_ŒoŠ´õÇupdate

5ŒŽ20“úi‹àj 13:15`14:55@2C‰ïêi2†ŠÙ2ŠK‰ï‹cŽº222{223j

À’·F
‹Tˆä@‘i“ú–{‘åŠwˆãŠw•”“à‰ÈŠwŒn_Œo“à‰ÈŠw•ª–ìj
 
…àV@‰p—mi“Œ‹žˆã‰ÈŽ•‰È‘åŠw‘åŠw‰@ˆãŽ•Šw‘‡Œ¤‹†‰È”]_Œo•a‘ÔŠwi_Œo“à‰ÈŠwjj
SY-20-1
’Pƒƒwƒ‹ƒyƒXƒEƒCƒ‹ƒXŠ´õÇ

‹Tˆä@‘i“ú–{‘åŠwˆãŠw•”“à‰ÈŠwŒn_Œo“à‰ÈŠw•ª–ìj

SY-20-2
HAMƒXƒyƒNƒgƒ‰ƒ€

‹v•Û“c@—´“ñiŽ­Ž™“‡‘åŠw“ƒEƒCƒ‹ƒX•a‘Ô§ŒäŒ¤‹†ƒZƒ“ƒ^[j

SY-20-3
ˆŸ‹}«d‰»«‘S”]‰Š

×–î@Œõ—ºi•Ÿ“‡Œ§—§ˆã‰È‘åŠw¬Ž™‰Èj

SY-20-4
is«‘½‘ƒ«”’Ž¿”]ÇiPMLj

…àV@‰p—mi“Œ‹žˆã‰ÈŽ•‰È‘åŠw‘åŠw‰@ˆãŽ•Šw‘‡Œ¤‹†‰È”]_Œo•a‘ÔŠwi_Œo“à‰ÈŠwjj

ƒVƒ“ƒ|ƒWƒEƒ€21
_Œo•Ï«Ž¾Š³‚Æ”]‘²’†‚̃ŠƒnƒrƒŠG—˜_‚ÆŽÀ‘H

5ŒŽ20“úi‹àj 13:15`14:45@2D‰ïêi2†ŠÙ2ŠK‰ï‹cŽº224j

À’·F
¶‹î@ˆêŒ›i–kŠC“¹‘åŠwƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“‰Èj
 
‹{ˆä@ˆê˜YiX”V‹{•a‰@_ŒoƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“Œ¤‹†•”j
SY-21-1
”]‘¹Œã‚Ì‹@”\‰ñ•œ‚Ì”]“à‹@\‚Æ_ŒoƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“

‹{ˆä@ˆê˜YiX”V‹{•a‰@_ŒoƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“Œ¤‹†•”j

SY-21-2
‹}«Šú‚©‚çŠJŽn‚·‚é”]‘²’†ƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“‚Ì—˜_‚ÆŽÀÛ

Œ´@Š°”üi‘ŠàV•a‰@ƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“‰Èj

SY-21-3
_ŒoŽ¾Š³‚ɑ΂·‚郊ƒnƒrƒŠƒe[ƒVƒ‡ƒ“‚Ì—˜_‚ÆŽÀ‘H

Œ´@sOi“ú–{ˆã‰È‘åŠwç—t–k‘•a‰@ƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“‰Èj

ƒVƒ“ƒ|ƒWƒEƒ€22
“«š‹‰ºáŠQ‚ɑ΂·‚鎡—Ãí—ªi‹¤ÃF“ú–{š‹‰ºˆãŠw‰ïj

5ŒŽ20“úi‹àj 13:15`14:45@2E‰ïêi2†ŠÙ3ŠK‰ï‹cŽº232{233j

À’·F
ˆäã@¹Œ[iŽD–yŽR‚Ìã•a‰@j
 
“¡“‡@ˆê˜Yi•l¼ŽsƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“•a‰@j
SY-22-1
“«š‹‰ºáŠQ‚ɑ΂·‚鎡—Ãí—ª‘˜_CƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“CŽèp

“¡“‡@ˆê˜Yi•l¼ŽsƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“•a‰@j

SY-22-2
”]‘²’†‚É‚æ‚éš‹‰ºáŠQ‚ɂ‚¢‚ÄWallenbergÇŒóŒQi‰„‘ŠO‘¤[Çj‚ð’†S‚É

‹“‡@•¶Žqi‹ž“s‘æˆêÔ\Žš•a‰@_Œo“à‰Èj

SY-22-3
ƒp[ƒLƒ“ƒ\ƒ“•aC‹ØˆÞk«‘¤õd‰»Ç‚ɑ΂·‚éš‹‰ºáŠQ‚Ì•]‰¿‚Æ‘Îô

ŽR–{@•q”Vi‘—§¸_E_Œoˆã—ÃŒ¤‹†ƒZƒ“ƒ^[_Œo“à‰Èj

ƒVƒ“ƒ|ƒWƒEƒ€23
_ŒoŽ¾Š³‚ɑ΂·‚é×–EŽ¡—Â̊J”­`Œ»ó‚Æ“W–]

5ŒŽ20“úi‹àj 13:15`14:45@2F‰ïêi2†ŠÙ3ŠK‰ï‹cŽº234j

À’·F
‚‹´@—Ç•ãi‹ž“s‘åŠw•a‰@_Œo“à‰Èj
 
¼–{@¹‘×iL“‡‘åŠw‘åŠw‰@ˆãŽ•–òŠw‘‡Œ¤‹†‰È‘n¶ˆã‰ÈŠwêU•a‘Ô’T‹†ˆã‰ÈŠwuÀ”]_Œo“à‰ÈŠwi‘æŽO“à‰Èjj
SY-23-1
’†•_ŒoŽ¾Š³‚ɑ΂·‚é×–EŽ¡—Â̓W–]‚ƉۑèiƒI[ƒo[ƒrƒ…[j

‚‹´@—Ç•ãi‹ž“s‘åŠw•a‰@_Œo“à‰Èj

SY-23-2
iPS×–E컋Zp‚ð—p‚¢‚½_Œo•Ï«Ž¾Š³‚ÌŒ¤‹†

ˆäã@Ž¡‹vi‹ž“s‘åŠwiPS×–EŒ¤‹†Š—Õ°‰ž—pŒ¤‹†•”–åj

SY-23-3
_Œo•ª‰»‚Æ‘¢Žîᇫ‚©‚ç”—‚éƒqƒgiPS×–E‚Ì•iŽ¿•]‰¿

‰ª“c@—m•½iŒcœä‹`m‘åŠw¶—Šwj

SY-23-4
SŒ´«”]ÇðÇŠ³ŽÒ‚ɑ΂·‚鎩ŒÈœ‘’PŠj‹…‚ð—p‚¢‚½×–EŽ¡—Â̗հŽŽŒ±

“cŒû@–¾•Fi‘—§zŠÂŠí•aŒ¤‹†ƒZƒ“ƒ^[”]_Œo“à‰Èj

ƒVƒ“ƒ|ƒWƒEƒ€24
‘n–òŒ¤‹†‚ð„i‚·‚邽‚߂ɂ͉½‚ª•K—v‚©H

5ŒŽ20“úi‹àj 13:15`14:45@3A‰ïêi3†ŠÙ3ŠK‘Û‰ï‹cŽºj

À’·F
ˆ¢•”@N“ñi‰ªŽR‘åŠw‘åŠw‰@ˆãŽ•–òŠw‘‡Œ¤‹†‰È_Œo•a‘Ô“à‰ÈŠwi_Œo“à‰Èjj
 
“c’†@ÍŒii–¼ŒÃ‰®‘åŠw_Œo“à‰Èj
SY-24-1
‹}‚ª‚Ήñ‚êF—Õ°Œ¤‹†ˆã‚ÌŒú‚¢‘w‚̈笂ÍC«—ˆ‚Ì‘n–òŒ¤‹†‚ðŽx‚¦‚é

•ŸŒ´@rˆêi‹ž“s‘åŠw‘åŠw‰@ˆãŠwŒ¤‹†‰Èˆã—ÉuŠw•ª–ìj

SY-24-2
ƒAƒJƒfƒ~ƒA‚Å‚Ìæ’[‘n–òE‘Šú’Tõ“I—Õ°ŠJ”­

‹{“c@•q’ji“Œ–k‘åŠw‘åŠw‰@ˆãŠwŒnŒ¤‹†‰È•‘®‘n¶‰ž—pˆãŠwŒ¤‹†ƒZƒ“ƒ^[j

SY-24-3
“ú–{‚ÆŠCŠO‚É‚¨‚¯‚é—Õ°ŽŽŒ±‚ÌŽÀî‚Æ¡Œã‚Ì“W–]

ˆêŠÛ@Ÿ•Fiˆã–ò•iˆã—Ë@Ší‘‡‹@\V–òR¸‘æŽO•”j

ƒVƒ“ƒ|ƒWƒEƒ€25
‚ß‚Ü‚¢‚Ì—Õ°FÅ‹ß‚Ìi•à

5ŒŽ20“úi‹àj 13:15`14:45@4A‰ïêi4†ŠÙ1ŠK”’’¹ƒz[ƒ‹i–kjj

À’·F
œA£@Œ¹“ñ˜Yióƒm쑇•a‰@”]_ŒoƒZƒ“ƒ^[j
 
•Ÿ•@•q•vi‹T“cƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[_Œo“à‰Èj
SY-25-1
ƒI[ƒo[ƒrƒ…[F‚ß‚Ü‚¢‚Ì—Õ°‚ð—‰ð‚µ‚悤

œA£@Œ¹“ñ˜Yióƒm쑇•a‰@”]_ŒoƒZƒ“ƒ^[j

SY-25-2
—Ç«”­ì«“ªˆÊ‚ß‚Ü‚¢Ç\f’f‚ÆŽ¡—ÂÌi•à

—é–Ø@åÊi“Œ‹žˆã‰È‘åŠwŽ¨•@ˆôA‰ÈŠw‹³Žºj

SY-25-3
”]Š²E¬”]‚ÌŒŒŠÇáŠQ‚É‚æ‚é‚ß‚Ü‚¢

é‘q@Œ’i•½’Ë‹¤Ï•a‰@_Œo“à‰Èj

SY-25-4
ƒqƒg‚Ì‘O’ë”玿

“à“¡@‘×i_ŒËŽs—§ˆã—ÃZƒ“ƒ^[’†‰›Žs–¯•a‰@Ž¨•@ˆôA‰Èj

SY-25-5
‚Ü‚Æ‚ß

•Ÿ•@•q•vi‹T“cƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[_Œo“à‰Èj

ƒVƒ“ƒ|ƒWƒEƒ€26
•Ï«Ž¾Š³‚̃V[ƒhE‹ÃWE_Œo‰ñ˜H–Ô“`”À‰¼à‚ÌŒŸØ

5ŒŽ20“úi‹àj 13:15`14:45@4B‰ïêi4†ŠÙ1ŠK”’’¹ƒz[ƒ‹i“ìjj

À’·F
’·’Jì@¬li“Œ‹ž“sˆãŠw‘‡Œ¤‹†Š”F’mǃvƒƒWƒFƒNƒgj
 
‘ºŽR@”É—Yi“Œ‹ž“sŒ’N’·Žõˆã—ÃZƒ“ƒ^[‚—îŽÒƒuƒŒƒCƒ“ƒoƒ“ƒNj
SY-26-1
˜Œ¾F‚—îŽÒƒuƒŒƒCƒ“ƒoƒ“ƒNƒvƒƒWƒFƒNƒg‚©‚ç‚ÌŽxŽ

‘ºŽR@”É—Yi“Œ‹ž“sŒ’N’·Žõˆã—ÃZƒ“ƒ^[‚—îŽÒƒuƒŒƒCƒ“ƒoƒ“ƒNj

SY-26-2
ƒvƒŠƒIƒ“•a‚©‚ç‚Ý‚½Š´õ‚·‚é’`”’‚Æ‚Í\Œ´“_‚Æ‚µ‚ẴvƒŠƒIƒ“•aup to date\

–k–{@“N”Vi“Œ–k‘åŠwˆãŠwŒnŒ¤‹†‰È•a‘Ô_ŒoŠwj

SY-26-3
_Œo•Ï«Ž¾Š³‚É‚¨‚¯‚é’`”’Šà‰¼à

’·’Jì@¬li“Œ‹ž“sˆãŠw‘‡Œ¤‹†Š”F’mǃvƒƒWƒFƒNƒgj

SY-26-4
ƒnƒ“ƒ`ƒ“ƒgƒ“•a‚ł̸_áŠQ”­Œ»‚É‚¨‚¯‚éƒNƒƒXƒV[ƒfƒBƒ“ƒO‰¼à\ƒvƒŠƒIƒ“•a‚©‚ç¸_E_ŒoŽ¾Š³‚Ö‚Ì“W–]\

“c’†@Œ³‰ëi—‰»ŠwŒ¤‹†Š”]‰ÈŠw‘‡Œ¤‹†ƒZƒ“ƒ^[“c’†Œ¤‹†ƒ†ƒjƒbƒgj

ƒVƒ“ƒ|ƒWƒEƒ€27
ƒI[ƒgƒtƒ@ƒW[‚Æ_Œo•Ï«‚ð‚ß‚®‚Á‚ÄF•a‘Ô‚©‚玡—ÂÖ

5ŒŽ20“úi‹àj 13:15`14:45@4C‰ïêi4†ŠÙ3ŠK‰ï‹cŽº432j

À’·F
¬¼@‰ë–¾i“Œ‹ž“sˆãŠw‘‡Œ¤‹†Šj
 
‰iˆä@‹`—²i‘—§¸_E_Œoˆã—ÃŒ¤‹†ƒZƒ“ƒ^[_ŒoŒ¤‹†ŠŽ¾•aŒ¤‹†‘æŽl•”j
SY-27-1
ƒXƒgƒŒƒX‰ž“š‹@\‚Æ‚µ‚Ä‚Ì‘I‘ð“IƒI[ƒgƒtƒ@ƒW[

¬¼@‰ë–¾i“Œ‹ž“sˆãŠw‘‡Œ¤‹†Šj

SY-27-2
•a“IƒAƒ“ƒhƒƒQƒ“Žó—e‘̶̂‘Ì“à•ª‰ðŒn‚ð—˜—p‚µ‚½‘|“¢

‘«—§@O–¾i–¼ŒÃ‰®‘åŠw_Œo“à‰Èj

SY-27-3
QBP1‚ð‰ž—p‚µ‚½ˆÙíL’·ƒ|ƒŠƒOƒ‹ƒ^ƒ~ƒ“’`”’Ž¿‚Ì“ÁˆÙ“I•ª‰ð

‰iˆä@‹`—²i‘—§¸_E_Œoˆã—ÃŒ¤‹†ƒZƒ“ƒ^[_ŒoŒ¤‹†ŠŽ¾•aŒ¤‹†‘æŽl•”j

ƒVƒ“ƒ|ƒWƒEƒ€28
“d‹C¶—‚©‚ç‚Ý‚½ALS‚Ì•a‘Ôupdate

5ŒŽ20“úi‹àj 15:00`17:00@2C‰ïêi2†ŠÙ2ŠK‰ï‹cŽº222{223j

À’·F
ŒKŒ´@‘iç—t‘åŠw_Œo“à‰Èj
 
‰€¶@‰ëOi’é‹ž‘åŠw_Œo“à‰Èj
SY-28-1
ALS‚Ì“d‹C¶—Šw“If’f‚ÌŽÀÛ

‰€¶@‰ëOi’é‹ž‘åŠw_Œo“à‰Èj

SY-28-2
ALS‚ł͉^“®_ŒoŽ²õ‚Ì–Œ“dˆÊ•Ï“®‚ª‘å‚«‚¢

“‡’J@‰ÀŒõi“¿“‡‘åŠw•a‰@_Œo“à‰Èj

SY-28-3
ALS‚Ì—\Œã‹K’èˆöŽq‚Æ‚µ‚Ẳ^“®_ŒoŽ²õ–Œ‹»•±“Á«

‹àˆä@”–¾iç—t‘åŠwˆãŠw•”•‘®•a‰@_Œo“à‰Èj

SY-28-4
TDP-43‹­§”­Œ»“®•¨ƒ‚ƒfƒ‹‚É‚¨‚¯‚é•a—E“d‹C¶—

‰¡“c@—²“¿i“Œ‹žˆã‰ÈŽ•‰È‘åŠw_Œo“à‰Èj

ƒVƒ“ƒ|ƒWƒEƒ€29
Ò‘¬”]•Ï«Çupdate

5ŒŽ20“úi‹àj 15:00`17:00@2D‰ïêi2†ŠÙ2ŠK‰ï‹cŽº224j

À’·F
²X–Ø@G’¼i–kŠC“¹‘åŠwˆãŠwŒ¤‹†‰È_Œo“à‰Èj
 
¼àV@³–LiVŠƒ‘åŠw•a‰@”]Œ¤‹†Š_Œo“à‰ÈŠw•ª–ìj
SY-29-1
¬”]‹@”\‚̶—Šw“I‰ðÍFŽžŠÔ•\Œ»‚̃ƒJƒjƒYƒ€

“c’†@^Ž÷i–kŠC“¹‘åŠwˆãŠwŒ¤‹†‰È¶—ŠwuÀ”F’ms“®Šw•ª–ìj

SY-29-2
SCA31‚Ì•ªŽq•a‘Ô‰ð–¾

Îì@‹Ô–çi“Œ‹žˆã‰ÈŽ•‰È‘åŠw_Œo“à‰Èj

SY-29-3
‚킪‘‚É‚¨‚¯‚éˆâ“`«áz«‘Ζƒáƒ‚ÌŒ»ó

‘ëŽR@‰Ã‹viŽR—œ‘åŠwˆãŠw•”_Œo“à‰ÈŠwuÀj

SY-29-4
¬”]«‰^“®Ž¸’²‚ɑ΂·‚郊ƒnƒrƒŠƒe[ƒVƒ‡ƒ“‚Ì—LŒø«

‹{ˆä@ˆê˜YiX”V‹{•a‰@_ŒoƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“Œ¤‹†•”j

ƒVƒ“ƒ|ƒWƒEƒ€30
ƒAƒ~ƒƒCƒh[ƒVƒXupdate

5ŒŽ20“úi‹àj 15:00`17:00@2E‰ïêi2†ŠÙ3ŠK‰ï‹cŽº232{233j

À’·F
’r“c@CˆêiMB‘åŠwˆãŠw•””]_Œo“à‰ÈCƒŠƒEƒ}ƒ`EäPŒ´•a“à‰Èj
 
ŽR“c@³mi‹à‘ò‘åŠw‘åŠw‰@ˆãŠwŒnŒ¤‹†‰È”]˜V‰»E_Œo•a‘ÔŠwi_Œo“à‰ÈŠwjj
SY-30-1
”ñ‰Æ‘°«ƒAƒ~ƒƒCƒh[ƒVƒX‚Ì—Õ°‚ƉuŠw

ŠÖ“‡@—ÇŽ÷iMB‘åŠwˆâ“`Žqf—Õ”j

SY-30-2
‰Æ‘°«ƒAƒ~ƒƒCƒh[ƒVƒX‚Ì—Õ°‚Æ•a—

¬’r@tŽ÷i–¼ŒÃ‰®‘åŠw_Œo“à‰Èj

SY-30-3
‰Æ‘°«ƒAƒ~ƒƒCƒhƒ|ƒŠƒjƒ…[ƒƒpƒ`[iFAPj‚ɑ΂·‚éŠÌˆÚA‚Ì—L—p«‚ÆŒÀŠE

ˆÀ“Œ@—RŠì—YiŒF–{‘åŠw¶–½‰ÈŠwŒ¤‹†•”•a‘Ôî•ñ‰ðÍŠwj

SY-30-4
”]ƒAƒ~ƒƒCƒhƒAƒ“ƒMƒIƒpƒ`[‚Ì—Õ°•a—

ŽR“c@³mi‹à‘ò‘åŠw‘åŠw‰@ˆãŠwŒnŒ¤‹†‰È”]˜V‰»E_Œo•a‘ÔŠwi_Œo“à‰ÈŠwjj

SY-30-5
ƒAƒ~ƒƒCƒh’`”’‚Ì‘ãŽÓ‰ñ“]‚ÆŽ¡—Âɂæ‚é‘Þk

’r“c@CˆêiMB‘åŠwˆãŠw•””]_Œo“à‰ÈCƒŠƒEƒ}ƒ`EäPŒ´•a“à‰Èj

ƒVƒ“ƒ|ƒWƒEƒ€31
•Ð“ª’É‚Ì–«‰»C“‰»‚̃ƒJƒjƒYƒ€‚ÆŽ¡—Ã

5ŒŽ20“úi‹àj 15:00`17:00@2F‰ïêi2†ŠÙ3ŠK‰ï‹cŽº234j

À’·F
—é–Ø@‘¥GiŒcœä‹`m‘åŠw•a‰@_Œo“à‰Èj
 
’†“‡@Œ’“ñi’¹Žæ‘åŠwˆãŠw•”ˆãŠw‰È”]_Œoˆã‰ÈŠwuÀ”]_Œo“à‰ÈŠw•ª–ìj
SY-31-1
•Ð“ª’É–«‰»‚̃ƒJƒjƒYƒ€

—é–Ø@‘¥GiŒcœä‹`m‘åŠw•a‰@_Œo“à‰Èj

SY-31-2
•Ð“ª’É‚ÌŒo‰ßEŽ©‘R—ð

ŒÃ˜a@‹v“Ti’¹Žæ‘åŠw”]_Œo“à‰Èj

SY-31-3
“«–ò•¨——p“ª’É‚ÌŽ¡—Ã

à_“c@ˆêi–k—¢‘åŠwˆãŠw•”_Œo“à‰ÈŠwj

SY-31-4
¸_‰ÈES—Óà‰È‚©‚ç‚̃Aƒvƒ[ƒ`

’[‹l@ŸŒhi“Œ–M‘åŠw‘åX•a‰@S—Óà‰Èj

ƒVƒ“ƒ|ƒWƒEƒ€32
_ŒoŽ¾Š³‚ɑ΂·‚éR‘̗Ö@

5ŒŽ20“úi‹àj 15:00`17:00@3A‰ïêi3†ŠÙ3ŠK‘Û‰ï‹cŽºj

À’·F
“c•½@•i‡“V“°‘åŠwˆãŠw•”•‘®‡“V“°ˆã‰@”]_Œo“à‰Èj
 
ŽR‘º@—²i‘—§¸_E_Œoˆã—ÃŒ¤‹†ƒZƒ“ƒ^[_ŒoŒ¤‹†Š–ƉuŒ¤‹†•”j
SY-32-1
MS/NMO‚ɑ΂·‚éR‘̗Ö@‚̉”\«

ŽR‘º@—²i‘—§¸_E_Œoˆã—ÃŒ¤‹†ƒZƒ“ƒ^[_ŒoŒ¤‹†Š–ƉuŒ¤‹†•”j

SY-32-2
‹ØŽ¾Š³‚ɑ΂·‚éRƒ}ƒCƒIƒXƒ^ƒ`ƒ“R‘̗Ö@‚ÌŠJ”­‚Ɖž—p

»“c@–FGiìèˆã‰È‘åŠw•a‰@_Œo“à‰ÈŠwj

SY-32-3
ƒAƒ‹ƒcƒnƒCƒ}[•a‚ɑ΂·‚éR‘̗Ö@

“c•½@•i‡“V“°‘åŠwˆãŠw•”•‘®‡“V“°ˆã‰@”]_Œo“à‰Èj

SY-32-4
‹ØˆÞk«‘¤õd‰»Ç‚ɑ΂·‚éR‘̗Ö@

Ž½’J@^iŽ ‰êˆã‰È‘åŠw•ªŽq_Œo‰ÈŠwŒ¤‹†ƒZƒ“ƒ^[j

ƒVƒ“ƒ|ƒWƒEƒ€33
ƒp[ƒLƒ“ƒ\ƒ“•a‚Ì•a‘Ô‚©‚ç—Õ°update

5ŒŽ20“úi‹àj 15:00`17:00@4A‰ïêi4†ŠÙ1ŠK”’’¹ƒz[ƒ‹i–kjj

À’·F
•ž•”@MFi‡“V“°‘åŠw”]_Œo“à‰Èj
 
ŽR–{@Œõ—˜i쌧—§’†‰›•a‰@_Œo“à‰Èj
SY-33-1
•a‘Ô

’·’Jì@—²•¶i“Œ–k‘åŠw•a‰@_Œo“à‰Èj

SY-33-2
•a—

ꎓ¡@—SŽqi‘—§¸_E_Œoˆã—ÃŒ¤‹†ƒZƒ“ƒ^[•a‰@—Õ°ŒŸ¸•”j

SY-33-3
ƒp[ƒLƒ“ƒ\ƒ“•aŽ¡—ÂÌup|to|date

”g“c–ì@‘ôi‡“V“°‘åŠwˆãŠw•”•‘®‡“V“°ˆã‰@”]_Œo“à‰Èj

ƒVƒ“ƒ|ƒWƒEƒ€34
”][ÇFTissue clock ‚ÆReperfusion

5ŒŽ20“úi‹àj 15:00`17:00@4B‰ïêi4†ŠÙ1ŠK”’’¹ƒz[ƒ‹i“ìjj

À’·F
–Ø‘º@˜a”üiìèˆã‰È‘åŠw•a‰@”]‘²’†ˆãŠwj
 
‚‹´@œÄˆêiŒcœä‹`m‘åŠw•a‰@_Œo“à‰Èj
SY-34-1
Tissue clock ‚ÆReperfusionFBrief overview

‚‹´@œÄˆêiŒcœä‹`m‘åŠw•a‰@_Œo“à‰Èj

SY-34-2
iv-tPAŽ¡—Ã4.5ŽžŠÔ‚Ü‚Å‚Ìtime window‚ÆMRI‚Ì“WŠJ

–Ø‘º@˜a”üiìèˆã‰È‘åŠw•a‰@”]‘²’†ˆãŠwj

SY-34-3
”]“®–¬ÄŠJ’ʗÖ@‚ÌŒ»ó‚Æ¡Œã

âˆä@MKi_ŒËŽs—§ˆã—ÃZƒ“ƒ^[’†‰›Žs–¯•a‰@”]_ŒoŠO‰Èj

SY-34-4
Tissue Clock Measurement Device‚Æ‚µ‚Ä‚ÌMRS

ŒÜ\—’@”Ž’†iVŠƒ‘åŠw”]Œ¤‹†Š“‡”]‹@”\Œ¤‹†ƒZƒ“ƒ^[j

SY-34-5
”][Ç‹}«ŠúŽ¡—ÂÌtherapeutic time window

ˆ¢•”@N“ñi‰ªŽR‘åŠw_Œo“à‰Èj

ƒVƒ“ƒ|ƒWƒEƒ€35
‰^“®ƒjƒ…[ƒƒ“Ž¾Š³‚Ì•ªŽq•a‘Ԃ̉𖾂Ǝ¡—Ö@ŠJ”­‚Ö‚Ì“W–]

5ŒŽ20“úi‹àj 15:00`17:00@4C‰ïêi4†ŠÙ3ŠK‰ï‹cŽº432j

À’·F
Š@—´™Zi“¿“‡‘åŠw_Œo“à‰Èj
 
Ÿ–ì@‰ë‰›i–¼ŒÃ‰®‘åŠw_Œo“à‰Èj
SY-35-1
TDP-43‚É‚æ‚é‰^“®ƒjƒ…[ƒƒ“•Ï«‚Ì•ªŽq•a‘Ô

–ì’†@—²i“Œ‹ž“sˆãŠw‘‡Œ¤‹†Šj

SY-35-2
Seipinopathy/Seipin/BSCL2ŠÖ˜A‰^“®ƒjƒ…[ƒƒ“Ž¾Š³\_Œo•Ï«‚É‚¨‚¯‚鬖E‘̃XƒgƒŒƒX‚Ìd—v«\

ˆÉ“Œ@‘å‰îiŒcœä‹`m‘åŠw•a‰@_Œo“à‰Èj

SY-35-3
Dynactin|1‚ð•W“I‚Æ‚µ‚½ŒÇ”­«ALSƒ‚ƒfƒ‹‚ÌŠJ”­

“c’†@ÍŒii–¼ŒÃ‰®‘åŠw_Œo“à‰Èj

SY-35-4
ALS ‚É‚¨‚¯‚éƒOƒŠƒAŠÖ˜A•a‘Ô

ŽR’†@G“ñi—‰»ŠwŒ¤‹†Š”]‰ÈŠw‘‡Œ¤‹†ƒZƒ“ƒ^[‰^“®ƒjƒ…[ƒƒ“•Ï«Œ¤‹†ƒ`[ƒ€j

SY-35-5
ŠÌ×–E‘BˆöŽq‚É‚æ‚éALS‚ɑ΂·‚éV‹KŽ¡—Ö@‚ÌŠJ”­

–Ø@³Žui“Œ–k‘åŠw•a‰@_Œo“à‰Èj

ƒy[ƒWƒgƒbƒv‚Ö↑

ƒ`[ƒ€ˆã—ÃŽÀ‘HƒvƒƒOƒ‰ƒ€

ƒe[ƒ}1@_ŒoŽ¾Š³‚É‚¨‚¯‚éƒPƒA‚ÌŽÀ‘H‚ƃŠƒXƒNƒ}ƒl[ƒWƒƒ“ƒg

5ŒŽ17“úi‰Îj 13:00`15:30@2B‰ïêi2†ŠÙ1ŠK“WŽ¦Žº212j

1C“]“|—\–h

À’·F
‹Àê@ˆèŽqi‘—§•a‰@‹@\“Œ–¼ŒÃ‰®•a‰@_Œo“à‰Èj
 
ìˆä@[i“Œé‹Ê•a‰@_Œo“à‰Èj

“]“|—\–h‚̃ƒJƒjƒYƒ€

‰‰ŽÒF
‰œò@GNi“ŒŒäŽs—§‚Ý‚Ü‚«‰·òf—Êj

_ŒoŽ¾Š³‚É‚¨‚¯‚é“]“|‚Ì“Á’¥

‰‰ŽÒF
‹Àê@ˆèŽqi‘—§•a‰@‹@\“Œ–¼ŒÃ‰®•a‰@_Œo“à‰Èj

“]“|—\–h‘Îô‚ÆŽÀ‘H

‰‰ŽÒF
‘ºˆä@“ÖŽqi‘—§•a‰@‹@\“Œ–¼ŒÃ‰®•a‰@ŠÅŒì•”j

“]“|—\–h‚Ì‚½‚߂̃ŠƒnƒrƒŠ

‰‰ŽÒF
ˆ¢•”@˜a•vi‘åã•ÛŒ’ˆã—ÑåŠwŒ¤‹†Žx‰‡ƒZƒ“ƒ^[j
ƒe[ƒ}1@_ŒoŽ¾Š³‚É‚¨‚¯‚éƒPƒA‚ÌŽÀ‘H‚ƃŠƒXƒNƒ}ƒl[ƒWƒƒ“ƒg

5ŒŽ17“úi‰Îj 15:45`18:15@2B‰ïêi2†ŠÙ1ŠK“WŽ¦Žº212j

2C‰h—{ŠÇ—

À’·F
‹{àV@–õi‹ßX•a‰@—Õ°‰h—{•”j
 
ŽR‰ª@˜NŽqi‘—§’·Žõˆã—ÃŒ¤‹†ƒZƒ“ƒ^[_Œo“à‰Èj

_ŒoŽ¾Š³Š³ŽÒ‚̉h—{ƒTƒ|[ƒg

‰‰ŽÒF
‹{àV@–õi‹ßX•a‰@—Õ°‰h—{•”j

_ŒoŽ¾Š³‚É‚¨‚¯‚é•a‘ԂƉh—{‰î“ü

‰‰ŽÒF
ŽR‰ª@˜NŽqi‘—§’·Žõˆã—ÃŒ¤‹†ƒZƒ“ƒ^[_Œo“à‰Èj

Œo’°‰h—{–@‚ÆŒoÖ¬‰h—{–@

‰‰ŽÒF
•Ð‘½@Žj–¾i‹T“c‘‡•a‰@_Œo“à‰Èj

_ŒoŽ¾Š³‚É‚¨‚¯‚éåñጂ̊Ǘ

‰‰ŽÒF
ˆéŠL@‘P‘ i‘—§’·Žõˆã—ÃŒ¤‹†ƒZƒ“ƒ^[æ’[f—Õ””畆‰Èj
ƒe[ƒ}2@‚ŽŸ”]‹@”\áŠQ‚ɑ΂·‚éƒPƒA‚ƃŠƒnƒrƒŠ‚ÌÅ‘Oü

5ŒŽ17“úi‰Îj 14:00`18:30@2A‰ïêi2†ŠÙ1ŠK“WŽ¦Žº211j

À’·F
•“c@ÍŒhi‘—§’·Žõˆã—ÃŒ¤‹†ƒZƒ“ƒ^[_Œo“à‰Èj
 
ŽR–{@³•Fiˆ¤’mŠw‰@‘åŠwSg‰ÈŠw•”j

‚ŽŸ”]‹@”\áŠQ‚̃PƒA‚ƃŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“

‰‰ŽÒF
Ží‘º@—¯”üi_ŒË‘åŠw‘åŠw‰@•ÛŒ’ŠwŒ¤‹†‰Èj

”F’mǂ̃PƒA‚ƃŠƒnƒrƒŠF_Œo“à‰È‚Ì—§ê‚©‚ç

‰‰ŽÒF
¡‘º@“OiVŠƒˆã—ÕŸŽƒ‘åŠw‘åŠw‰@ˆã—ÕŸŽƒŠwŒ¤‹†‰È•ÛŒ’ŠwêUŒ¾Œê’®ŠoŠw•ª–ìj

”F’mǂ̃PƒA‚ƃŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“G¸_‰È‚Ì—§ê‚©‚ç

‰‰ŽÒF
ŽO‘º@›’iŒcœä‹`m‘åŠwˆãŠw•”¸__Œo‰Èj

Ž¸Œêǂ̃PƒA‚ƃŠƒnƒrƒŠ

‰‰ŽÒF
‘å’Î@”ü‰Ài–kŠC“¹‘åŠw‘åŠw‰@•ÛŒ’‰ÈŠwŒ¤‹†j
ƒe[ƒ}3@CI—Ö@K“¾ƒvƒƒOƒ‰ƒ€

5ŒŽ17“úi‰Îj 14:00`16:30@2C‰ïêi2†ŠÙ2ŠK‰ï‹cŽº222{223j

À’·F
›ŽìŽR@–«i–¼ŒÃ‰®‘åŠw•ÛŒ’Šw‰Èj

CI—Ö@K“¾ƒZƒ~ƒi[

‰‰ŽÒF
“¹–Æ@˜a‹vi•ºŒÉˆã‰È‘åŠwƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“ˆãŠw‹³Žºj
ƒe[ƒ}1@_ŒoŽ¾Š³‚É‚¨‚¯‚éƒPƒA‚ÌŽÀ‘H‚ƃŠƒXƒNƒ}ƒl[ƒWƒƒ“ƒg

5ŒŽ18“úi…j 8:30`10:10@2A‰ïêi2†ŠÙ1ŠK“WŽ¦Žº211j

3C_Œo‹ØŽ¾Š³‚É‚¨‚¯‚éŒÄ‹zƒPƒA

À’·F
’†“‡@Fi‘—§•a‰@‹@\VŠƒ•a‰@_Œo“à‰Èj
 
•Ÿ‰i@G•qi‘—§•a‰@‹@\“ì‹ãB•a‰@j

ŒÄ‹z•s‘S‚ɑ΂·‚éŒÄ‹zƒPƒA‘˜_

‰‰ŽÒF
’±–¼—Ñ@’¼•Fi¹˜H‰Á‘Û•a‰@ŒÄ‹zŠí“à‰Èj

‹ØƒWƒXƒgƒƒtƒB[‚É‚¨‚¯‚éŒÄ‹zƒPƒA

‰‰ŽÒF
Îì@—I‰Ái‘—§•a‰@‹@\”ª‰_•a‰@¬Ž™‰Èj

ALS‚̕“IŒÄ‹zƒPƒA

‰‰ŽÒF
¬X@“N•vi‘—§•a‰@‹@\” ª•a‰@j

_Œo‹ØŽ¾Š³‚̌ċzŠíƒPƒA‚É‚¨‚¯‚é—Šw—Ö@‚Ì–ðŠ„

‰‰ŽÒF
‹e’n@–Li”]ŒŒŠÇŒ¤‹†Š”üŒ´‹L”O•a‰@_Œo“ï•aƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“‰Èj

ŒÄ‹zƒPƒA‚É‚¨‚¯‚éŠÅŒìƒPƒA‚Ì–ðŠ„

‰‰ŽÒF
’†ŽR@—D‹Gi“Œ‹ž“sˆãŠw‘‡Œ¤‹†Š“ï•aƒPƒAŠÅŒìŒ¤‹†•”–åj
ƒe[ƒ}1@_ŒoŽ¾Š³‚É‚¨‚¯‚éƒPƒA‚ÌŽÀ‘H‚ƃŠƒXƒNƒ}ƒl[ƒWƒƒ“ƒg

5ŒŽ18“úi…j 10:10`11:40@2A‰ïêi2†ŠÙ1ŠK“WŽ¦Žº211j

4CÛHš‹‰º

À’·F
“¡–{@•ÛŽui–¼ŒÃ‰®‘åŠwŽ¨•@ˆôA‰Èj
 
–xŒû@—˜”Vi–k—¢‘åŠwˆã—Éq¶Šw•”ƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“Šw‰Èj

_Œo‹ØŽ¾Š³‚É‚¨‚¯‚éÛHEš‹‰ºáŠQ‚Ì•a‘ԂƑΉž

‰‰ŽÒF
–ìè@‰€Žqi•ºŒÉˆã—ÑåŠwƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“Šw•”j

ÛHEš‹‰ºáŠQŠ³ŽÒ‚̃ŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“`Œ¾Œê’®ŠoŽm‚Ì—§ê‚©‚ç`

‰‰ŽÒF
´…@[Žqié‹ÊŒ§‘‡ƒŠƒnƒrƒŠƒZƒ“ƒ^[Œ¾Œê’®Šo‰Èj

_ŒoŽ¾Š³‚É‚¨‚¯‚éš‹‰ºáŠQŠ³ŽÒ‚̃PƒA\ÛHEš‹‰ºáŠQŠÅŒì”F’èŠÅŒìŽt‚Ì—§ê‚©‚ç\

‰‰ŽÒF
“¡X@‚Ü‚èŽqi¹—êŽO•ûŒ´•a‰@ŠÅŒì‘Š’kŽºj

š‹‰ºŽ¡—Ẫ`[ƒ€Ž¡—ÂƈãŽt‚Æ‚µ‚ẴŠƒXƒNŠÇ—

‰‰ŽÒF
’Óc@‹‘¾i•ŸˆäŒ§Ï¶‰ï•a‰@Ž¨•@ˆôA‰ÈEèò•”ŠO‰Èj
ƒe[ƒ}4@Lee Silverman Voice TreatmentiLSVTjK“¾ƒvƒƒOƒ‰ƒ€

5ŒŽ19“úi–Øj 9:45`13:00/14:00`18:20@2A‰ïêi2†ŠÙ1ŠK“WŽ¦Žº211j
5ŒŽ20“úi‹àj 8:30`11:50/13:00`16:30@2A‰ïêi2†ŠÙ1ŠK“WŽ¦Žº211j

ƒy[ƒWƒgƒbƒv‚Ö↑

’©‚©‚ç”Ó‚Ü‚Å_Œo“à‰È

1D‚æ‚­‚í‚©‚éÒ‘MRI‚ÌŒ©•û

5ŒŽ18“úi…j 8:30`9:15@1D‰ïêi1†ŠÙ4ŠK‰ï‹cŽº141{142j

À’·F
ˆäã@¹Œ[iŽD–yŽR‚Ìã•a‰@Ò’ÅEÒ‘ƒZƒ“ƒ^[j
‰‰ŽÒF
‹TŽR@—²iŒ§—§‘½Ž¡Œ©•a‰@_Œo“à‰Èj
2D‚æ‚­‚í‚©‚铪•”MRI‚ÌŒ©•û

5ŒŽ18“úi…j 9:15`10:00@1D‰ïêi1†ŠÙ4ŠK‰ï‹cŽº141{142j

À’·F
ŽR˜e@Œ’·iL“‡‘åŠw”]_Œo“à‰Èj
‰‰ŽÒF
–ö‰º@Íi“s—§_Œo•a‰@_Œo•úŽËü‰Èj
3D‚æ‚­‚í‚©‚éŠjˆãŠwf’f

5ŒŽ18“úi…j 10:00`10:45@1D‰ïêi1†ŠÙ4ŠK‰ï‹cŽº141{142j

À’·F
•ŸŽR@G’¼i‹ž“s‘åŠw”]‹@”\‘‡Œ¤‹†ƒZƒ“ƒ^[j
‰‰ŽÒF
ˆÉ“¡@Œ’Œái‘—§’·Žõˆã—ÃŒ¤‹†ƒZƒ“ƒ^[”F’mÇæiˆã—ÊJ”­ƒZƒ“ƒ^[”]‹@”\‰æ‘œf’fŠJ”­•”j
4D‚æ‚­‚í‚©‚鬎™‘ãŽÓ«Ž¾Š³

5ŒŽ19“úi–Øj 8:30`9:15@1D‰ïêi1†ŠÙ4ŠK‰ï‹cŽº141{142j

À’·F
¼–ì@ˆêŽOi‘—§¸_E_Œoˆã—ÃŒ¤‹†ƒZƒ“ƒ^[_ŒoŒ¤‹†ŠŽ¾•aŒ¤‹†‘æˆê•”j
‰‰ŽÒF
‘å–ì@kôi’¹Žæ‘åŠw”]_Œo¬Ž™‰Èj
5D‚æ‚­‚í‚©‚鬔]Ž¸’²Ç

5ŒŽ19“úi–Øj 9:15`10:00@1D‰ïêi1†ŠÙ4ŠK‰ï‹cŽº141{142j

À’·F
¼àV@³–LiVŠƒ‘åŠw•a‰@”]Œ¤‹†Š_Œo“à‰ÈŠw•ª–ìj
‰‰ŽÒF
Îì@‹Ô–çi“Œ‹žˆã‰ÈŽ•‰È‘åŠw_Œo“à‰Èj
6Dƒ~[ƒgEƒUEƒGƒLƒXƒp[ƒg

5ŒŽ19“úi–Øj 10:00`11:10@1D‰ïêi1†ŠÙ4ŠK‰ï‹cŽº141{142j

À’·F
–ö@–±i”F’mljîŒìŒ¤‹†EŒ¤C‘å•{ƒZƒ“ƒ^[j
‰‰ŽÒF
Šâ“c@½i“Œ‹ž—Žqˆã‰È‘åŠw–¼—_‹³Žöj
 
ûü‹´@ºi–¼ŒÃ‰®‘åŠw–¼—_‹³Žö/“ŒŠC’†‰›•a‰@–¼—_‰@’·j
7D‚æ‚­‚í‚©‚éˆã—Ë@ŠíiBipapCPEG“™j

5ŒŽ19“úi–Øj 11:10`11:50@1D‰ïêi1†ŠÙ4ŠK‰ï‹cŽº141{142j

À’·F
“’ó@—´•Fiç—t_Œo“ï•aˆã—ÃZƒ“ƒ^[j
‰‰ŽÒF
’†“‡@Fi‘—§•a‰@‹@\VŠƒ•a‰@_Œo“à‰Èj
8D‚æ‚­‚í‚©‚é•sˆÓ‰^“®‚ÌŒ©•û

5ŒŽ19“úi–Øj 13:15`14:00@1D‰ïêi1†ŠÙ4ŠK‰ï‹cŽº141{142j

À’·F
‹ß“¡@’q‘Pi˜a‰ÌŽRŒ§—§ˆã‰È‘åŠw_Œo“à‰Èj
‰‰ŽÒF
’·’Jì@ˆêŽqi‘—§•a‰@‹@\‘Š–ÍŒ´•a‰@_Œo“à‰Èj
9D‚æ‚­‚í‚©‚éƒp[ƒLƒ“ƒ\ƒjƒYƒ€‚𗈂·Ž¾Š³‚ÌŠÓ•Ê

5ŒŽ19“úi–Øj 14:00`14:45@1D‰ïêi1†ŠÙ4ŠK‰ï‹cŽº141{142j

À’·F
–쌳@³Oiˆ¤•Q‘åŠwˆãŠw•”•‘®•a‰@–ò•¨—Ö@E_Œo“à‰Èj
‰‰ŽÒF
ŽO—Ö@‰pli˜a‰ÌŽRŒ§—§ˆã‰È‘åŠw_Œo“à‰Èj
10D‚æ‚­‚í‚©‚鎩—¥_Œo‹@”\ŒŸ¸

5ŒŽ19“úi–Øj 15:00`16:00@1D‰ïêi1†ŠÙ4ŠK‰ï‹cŽº141{142j

À’·F
’·’Jì@N”Ži–¼ŒÃ‰®‘æ“ñÔ\Žš•a‰@_Œo“à‰Èj
‰‰ŽÒF
š –{@‰ë–çi϶‰ï•a‰@_“Þ쌧•a‰@_Œo“à‰Èj
 
D–Î@’q”ViŠÖ“Œ’†‰›•a‰@_Œo“à‰Èj
11D‚æ‚­‚í‚©‚éÒ‘Ž¾Š³‚ÌŒ©•û

5ŒŽ19“úi–Øj 16:00`16:45@1D‰ïêi1†ŠÙ4ŠK‰ï‹cŽº141{142j

À’·F
Š‹Œ´@–ÎŽ÷i—鎭ˆã—ÉȊw‘åŠw•ÛŒ’‰q¶Šw•”ˆã—ÕŸŽƒŠw‰Èj
‰‰ŽÒF
ˆÀ“¡@“N˜NiˆÀéX¶•a‰@_Œo“à‰ÈCˆã—ÈÀ‘Sj
12D‚æ‚­‚í‚©‚é—U”­‹Ø“d}

5ŒŽ20“úi‹àj 8:00`9:00@1D‰ïêi1†ŠÙ4ŠK‰ï‹cŽº141{142j

À’·F
›ŽìŽR@–«i–¼ŒÃ‰®‘åŠw•ÛŒ’Šw‰Èj
‰‰ŽÒF
KŒ´@L•vi_ŒËŽs—§ˆã—ÃZƒ“ƒ^[’†‰›Žs–¯•a‰@_Œo“à‰Èj
13D—Õ°ŽŽŒ±‚É‚¨‚¯‚é“ŒvŠw“Il‚¦•û

5ŒŽ20“úi‹àj 9:00`9:45@1D‰ïêi1†ŠÙ4ŠK‰ï‹cŽº141{142j

À’·F
àV“c@GKi‘—§•a‰@‹@\‰F‘½–ì•a‰@_Œo“à‰Èj
‰‰ŽÒF
ãâ@_”Vi‘åã‘åŠw—Õ°ˆãHŠw—Z‡Œ¤‹†‹³ˆçƒZƒ“ƒ^[j
14D‚æ‚­‚í‚©‚鎡Œ±EƒRƒz[ƒgŒ¤‹†

5ŒŽ20“úi‹àj 9:45`10:30@1D‰ïêi1†ŠÙ4ŠK‰ï‹cŽº141{142j

À’·F
¼–{@¹‘×iL“‡‘åŠw”]_Œo“à‰ÈŠwj
‰‰ŽÒF
ŽR–{@°Žqi‘—§zŠÂŠí•aŒ¤‹†ƒZƒ“ƒ^[”]ŒŒŠÇ“à‰Èj
15Dƒ~[ƒgEƒUEƒGƒLƒXƒp[ƒg

5ŒŽ20“úi‹àj 13:15`14:15@1D‰ïêi1†ŠÙ4ŠK‰ï‹cŽº141{142j

À’·F
ŽR–{@ú\Žqi“¡“c•ÛŒ’‰q¶‘åŠw–¼—_‹³Žöj
‰‰ŽÒF
…–ì@”ü–Mi–k—¢‘åŠwˆãŠw•”_ŒoĶˆã—ÊwuÀj
 
ŽÄè@_i‹ž“s‘åŠw–¼—_‹³Žöj
16D‚ ‚È‚½‚ÍŒ©—Ž‚Æ‚µ‚Ä‚¢‚Ü‚¹‚ñ‚©H‚±‚ñ‚È”][Ç

5ŒŽ20“úi‹àj 14:15`15:00@1D‰ïêi1†ŠÙ4ŠK‰ï‹cŽº141{142j

À’·F
Ž›ŽR@–õ•viŠâŽèˆã‰È‘åŠw_Œo“à‰ÈE˜V”N‰È•ª–ìj
‰‰ŽÒF
–L“c@ˆê‘¥i‘—§zŠÂŠí•aŒ¤‹†ƒZƒ“ƒ^[”]ŒŒŠÇ“à‰Èj
17D‚æ‚­‚í‚©‚é’†•_Œo•a—i1j

5ŒŽ20“úi‹àj 15:00`16:00@1D‰ïêi1†ŠÙ4ŠK‰ï‹cŽº141{142j

À’·F
‹´‹l@—Ç•vi•ŸŽƒ‘º•a‰@_Œo•a—Œ¤‹†Šj
‰‰ŽÒF
‚‹´@‹ÏiVŠƒ‘åŠw”]Œ¤‹†Š•a‘Ô_Œo‰ÈŠw•”–å•a—Šwj
 
Žá—Ñ@FˆêiO‘O‘åŠw”]_Œo•a—Šwj
18D‚æ‚­‚í‚©‚é’†•_Œo•a—i2j

5ŒŽ20“úi‹àj 16:00`17:00@1D‰ïêi1†ŠÙ4ŠK‰ï‹cŽº141{142j

À’·F
‹´‹l@—Ç•vi•ŸŽƒ‘º•a‰@_Œo•a—Œ¤‹†Šj
‰‰ŽÒF
‘ºŽR@”É—Yi“Œ‹ž“sŒ’N’·Žõˆã—ÃZƒ“ƒ^[‚—îŽÒƒuƒŒƒCƒ“ƒoƒ“ƒNj
 
‹g“c@áÁ—iˆ¤’mˆã‰È‘åŠw‰Á—îˆã‰ÈŠwŒ¤‹†Šj